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ABSTRACT
Cyclooxygenase (COX) is the key enzyme in the biosynthesis of prostaglandins 
(PGs) known as pro-inflammatory mediators. COX has two isoforms: the constitutively 
expressed COX-1 and the mitogen-inducible COX-2. It has been demonstrated that 
COX-2 expression is selectively induced by lipopolysaccharide (LPS) treatment after 
several hours in rat alveolar macrophages (Lee et al., 1992; Chanmugam et al., 1995) 
and RAW 264.7 macrophages (Gang, 1996). The mitogen-activated protein kinases 
[MAPKs; extracellular signal-regulated kinases (ERKs), P38, and c-jun N-terminal 
kinases (JNKs)], nuclear factor kappa B (NF-kB), and Lyn kinase are known to be 
activated in the early stages (within minutes) o f LPS signaling pathways. In the current 
study, the mechanism of COX-2 expression induced by LPS in RAW 264.7 
macrophages was examined.
To examine the involvement of MAPKs and NF-kB on COX-2 expression,
RAW 264.7 cells were treated with LPS and known activators and inhibitors of 
MAPKs, NF-kB, or protein tyrosine kinases (PTKs). To examine the role of Lyn kinase 
on COX-2 expression, Phoenix (<t>NX) cells, a  packaging cell line, were transfected 
with Flag (epitope)-tagged lyn cDNAs in the retroviral vector pBPSTRl, and the 
infectious viral particles produced by transfected d>NX cells were infected to NIH/3T3 
cells, a murine fibroblast cell line.
The activation of MAPKs by known activators was insufficient to induce COX-2 
expression. Partial inhibition o f LPS-induced activation o f MAPKs by PD98059 or 
SB203580 resulted in partial inhibition of COX-2 expression. Similarly, inhibition of 
LPS-induced activation of NF-kB by Z-LLF-CHO resulted in suppression of COX-2
vi
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expression. Both inhibition of LPS-induced activation of MAPKs and NF-kB by 
Radicicol or Herbimycin A resulted in suppression o f COX-2 expression. Transfection 
data lead to an observation that high COX-2 expression and PGE2 levels can be induced 
by overexpression of mutant Lyn in NIH/3T3 cells transfected with mutant lyn DNA.
This study demonstrates that COX-2 expression induced by LPS in RAW 264.7 
cells appears to be mediated via rapid activation of MAPKs and NF-kB in LPS 
signaling pathways.
vii
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CHAPTER 1 
INTRODUCTION
Cyclooxygenase (COX, or prostaglandin H (PGH) synthase) is the key enzyme 
that catalyzes the first step of the conversion of arachidonic acid and other related 
unsaturated fatty acids to prostaglandin endoperoxide. These in turn are converted to 
various prostaglandins (PGs) and thromboxanes (TXs), which exert diverse 
pathophysiological actions (Merlie et al., 1988; DeWitt et a l, 1988). Two isoforms of 
COX have been identified: the constitutively expressed COX-1 (DeWitt et al., 1988; 
Merlie etal., 1988; Yokoyama etal., 1988; DeWitt etal., 1990; Yokoyama etal., 1989) 
and the mitogen-inducible COX-2 (Kujubu et a l, 1991; Xie et al., 1991; O’Banion et 
al., 1991; Hla et al., 1992; Jones et a l,  1993; Feng et al., 1993). COX-1 is 
constitutively expressed in most cell types, and PGs produced by COX-1 may have 
some beneficial physiological functions, such as the antithrombogenic action of 
prostacyclin released by the vascular endothelium, and the cytoprotective effect of PGs 
produced by the gastric mucosa (Whittle et al., 1980). On the other hand, the 
expression of COX-2 is induced following the activation of cells by various 
proinflammatory agents including cytokines (Hla et a l, 1992; Feng et a l,  1993; Feng et 
al., 1995) and other mitogens (Kujubu et a l, 1991; O’Banion et al., 1991; Hla et a l,
1992). These observations suggest that COX-2 instead of COX-1 may be responsible 
for the production of PGs involved in inflammation. It has been shown that COX-2 is 
selectively expressed in LPS-stimulated rat alveolar macrophages (Lee et al., 1992; 
Chanmugam et a l, 1995) and RAW 264.7 macrophages (Gang, 1996). However, the 
signal transduction pathway induced by LPS that leads to the expression of COX-2 in
1
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macrophages is not clearly understood. The stimulation of macrophages by LPS 
treatment results in activation of mitogen-activated protein kinases (MAPKs), such as 
ERK-1 & ERK-2 (extracellular signal-regulated protein kinase-1 & -2, also designated 
as MAPK-1 & MAPK-2), P38, and JNKs/SAPKs (c-jun N-terminal kinases/stress- 
activated protein kinases) (Weinstein et al., 1992; Han et al., 1993; Hambleton et al., 
1996). These MAPKs are distinguished by the sequence o f the tripeptide dual 
phosphorylation motif that is required for their activation: Thr-Glu-Tyr (ERKs), Thr- 
Pro-Tyr (JNKs), and Thr-Gly-Tyr (P38 MAP kinase) (Derijard et al., 1995). ERK-1 and 
ERK-2 require dual phosphorylation of both Threonine-183 and Tyrosine-185 for 
activation (Payne et al., 1991). The immediate upstream protein kinases that 
phosphorylate these residues in ERK-1 and ERK-2 are MAPK Kinase-1 (the same as 
MEK-1 or MKK-1) and MAPK Kinase-2 (the same as MEK-2 or MKK-2), respectively. 
MEK-1 and MEK-2 possess dual specificity for the threonine and tyrosine residues in 
ERK-1 and ERK-2 (Ahn et al., 1991; Seger et al., 1991; Campbell et al., 1991). The 
signaling pathway of MAPKs is one o f the major signaling pathways transmitting 
signals from growth factors, hormones, and cytokines to the immediate early genes, 
which are genes induced by a stimulus in the absence of de novo synthesis of proteins. 
Activated MAPKs, in turn, can activate distinct transcription factors that bind c/5-acting 
elements of the immediate early genes (Karin et al., 1995).
It has been clearly demonstrated that the promoter regions o f COX-2 genes in 
different species contain cis-acting elements such as CRE, AP2, SP1, and NF-IL6 
(Fletcher et al., 1992; Sirois et al., 1993; Inoue et al., 1995; Yamamoto etal., 1995; 
Kosaka et al., 1994) which can be transactivated by MAPK-activated transcription
2
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factors (Davis, 1994; Karin et al., 1995). As recently as 1998, Guan et al. assumed that 
the signaling pathway of MAPKs functions as an important regulator of prostaglandin 
biosynthesis. SB203580, one o f the novel classes o f cytokine-suppressive anti­
inflammatory drugs (CSAID), has been shown to be an inhibitor of LPS-stimulated 
tumor necrosis factor (TNF) and interleukin-1 (IL-1) induction. SB203580 is known to 
inhibit the catalytic activity of P38 MAP kinase (Lee et al., 1994). These investigators 
also have implicated the role of the P38 MAP kinase and the JNK/SAPK pathway in the 
regulation of cytokine production and inflammatory mediators. The inhibition of P38 
MAP kinase by SC68376, another P38 MAP kinase inhibitor, inhibited cytokine- 
induced stimulation of COX-2 and PGE2 production, suggesting that the signaling 
pathway of P38 MAP kinase is one of the important signaling mechanisms modulating 
cytokine-induced COX-2 expression and prostaglandin biosynthesis (Guan et al., 1997). 
These observations serve to potentially link prostaglandin biosynthetic pathways, which 
mediate inflammatory responses, with the signaling pathway of MAPKs (Guan et al., 
1998).
It has been shown that PD98059 selectively inhibits the kinase activity of MEK- 
1 and MEK-2 (Pang et al., 1995), which are the upstream activators that phosphorylate 
and activate ERK-1 and ERK-2 in most cell types. In the current study, these specific 
inhibitors of MAPKs, PD98059 and SB203580, were used to determine whether LPS- 
induced activation o f MAPKs (particularly ERK-1, ERK-2, or P38 MAP kinase) are 
involved in the expression of COX-2 in LPS-stimulated RAW 264.7 macrophages.
In macrophages, LPS treatment also results in the activation of the nuclear 
factor-kappa B (NF-kB) transcription factor, which leads to the induction of immediate
3
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early gene expression (Baeuerle, 1991). The cw-acting NF-kB element, which is a 
specific DNA sequence recognized by NF-kB transcription factor, is known to be 
present in the promoter regions of the COX-2 gene (Yamamoto et al., 1995; Fletcher et 
a l, 1992; Sirois et al., 1993; Inoue et al., 1995; Kosaka et al., 1994). In most resting 
cells, NF-kB is retained in the cytoplasm in an inactive form because an inhibitory 
protein, IkB-a, is associated with NF-kB, thereby preventing its nuclear translocation. 
Certain extracellular stimuli cause degradation of IkB-a, resulting in the release of free 
and active NF-kB, which translocates to the nucleus and induces gene transcription 
through the cw-acting kB element in transcribed genes (Siebenlist et al., 1994). The 
activation of NF-kB correlates with rapid proteolytic degradation of IkB-a regardless of 
signals or cell types (Brown et al., 1993; Sun et al., 1993). DiDonato et al. (1995) used 
Vinitsky’s multicatalytic protease complex (MPC) inhibitor Z-LLF-CHO (benzyloxy- 
carbonyl-Leu-Leu-phenylalaninal) to demonstrate that the degradation of IkB-a is 
required for NF-kB activation. Using this inhibitor o f NF-kB, we examined whether 
inhibition of LPS-induced NF-kB activation results in the suppression of COX-2 
expression in LPS-stimulated RAW 264.7 macrophages. This experiment reveals that 
the degradation of IkB-a induced by LPS treatment indicates NF-kB activation.
It has been suggested that protein tyrosine kinases (PTKs) might regulate cell 
proliferation and differentiation (Fantl et al., 1993; Ullrich and Schlessinger, 1990). 
Many growth factor receptors and oncogene products are believed to possess PTK 
activity. Two types of PTKs have been identified: receptor type and non-receptor type. 
PTKs of receptor type participate in transmembrane signal transduction pathways.
PTKs o f non-receptor type participate in intracellular signal transduction pathways.
4
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PTKs of non-receptor type include Src family PTKs. So far, nine Src-family tyrosine 
kinases have been identified (Src, Lyn, Fgr, Hck, Fyn, Yes, Lck, Blk, and Yrk) (Brown 
and Cooper, 1996). Src family PTKs are highly homologous in structure; they all 
contain an N-terminal myristylation domain, Src homology 2 (SH2) and Src homology 3 
(SH3) domain, a protein kinase domains (catalytic), and a C-terminal regulatory domain 
(Brown and Cooper, 1996).
Two major consensus tyrosine phosphorylation sites have been identified in Src 
family PTKs: (1) the tyrosine autophosphorylation site in the protein kinase domain and 
(2) the tyrosine phosphorylation site in the C-terminal regulatory domain. 
Autophosphorylation on tyrosine residue in the protein kinase domain correlates with 
Src PTK’s activation, while phosphorylation of tyrosine residue at the C-terminal 
regulatory domain negatively suppresses their kinase activities (Cooper et al., 1986). A 
C-terminal Src kinase (Csk) phosphorylates the tyrosine residue at the C-terminal 
regulatory domain in several members of the Src family tyrosine kinases and is thought 
to play a critical role in negatively regulating kinase activity. Several lines of evidence 
suggest that this regulation is governed by an intramolecular interaction between the 
phosphorylated tyrosine residue in the C-terminal regulatory domain and the SH2 
domain which stabilizes an inactive conformation of the Src family PTKs.
Some Src family PTKs, in association with cell surface proteins, participate in 
normal signaling pathways in hemopoietic cells including monocytes and macrophages 
(Bolen et al., 1992). The initial interaction of LPS with monocytes and macrophages 
involves a LPS-binding protein (LBP) that binds to LPS and a receptor CD 14, which is 
a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein (Han et al.,
5
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1993). Comparatively less is known about intracellular signaling events after binding o f 
LPS to CD 14 (Ulevitch et al., 1995). Among 9 members of the Src family PTKs, Lyn, 
Hck, and Fgr are strong candidates for the primary signal transducers o f LPS responses 
in monocytes and macrophages (Meng et al., 1997). All three o f these kinases are 
rapidly activated following LPS treatment.
A portion of intracellular Lyn directly co-associates with CD 14 in human 
monocytes (Stefanova et al., 1993). It has been shown that PTK inhibitors that inhibit 
the expression of COX-2 also reduce the tyrosine phosphorylation of Lyn PTK in rat 
alveolar macrophages stimulated with LPS (Chanmugam et al., 1995). These 
observations suggest that Src PTKs may be an upstream activator and play critical roles 
in LPS-initiated or LPS/CD14-mediated signal transduction pathways, leading to the 
expression of COX-2 in monocytes and macrophages. Many immediate early genes, 
including the COX gene, are induced in Rous sarcoma virus (RS V)-infected chicken 
embryo fibroblasts (CEFs) in which v-srcp60 (the tyrosine residue in the C-terminal 
regulatory domain was mutated to phenylalanine) is constitutively expressed (Xie et al.,
1991). This suggests a critical role o f the tyrosine residue at the C-terminal regulatory 
domain in negatively regulating the activity of Src PTKs and also implies that the 
expression of many immediate early genes, including COX-2 gene, might be induced in 
other cell types by a single amino acid change (the tyrosine residue in the C-terminal 
regulatory domain) in other Src PTKs. In the current study, transfection using wild 
(normal) and mutant (the tyrosine residue in the C-terminal regulatory domain was 
mutated to phenylalanine) lyn DNA was used to examine whether overexpression of 
mutant Lyn induces the expression of COX-2 in NIH/3T3 cells.
6
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1.1. Research Objectives
The overall goal of the research presented in this dissertation was to examine the 
LPS signal transduction pathways that affect the expression of COX-2 in LPS- 
stimulated RAW 264.7 macrophages. The specific goals are to determine whether 
MAPKs, NF-kB, and Lyn kinase, which have been known to be activated in LPS 
signaling pathways, are involved in the expression of COX-2. These studies were 
carried out by (1) examination of whether the signaling pathway of LPS-induced 
activation of MAPKs alone is sufficient to induce the expression of COX-2 in RAW 
264. 7 macrophages using known activators o f MAPKs, such as PMA, sorbitol, H2O2, 
or a combination of these factors; (2) examination of whether inhibition o f  LPS-induced 
activation of MAPKs results in the inhibition of COX-2 expression in LPS-stimulated 
RAW 264.7 macrophages by using the inhibitors of MAPKs such as PD98059 (MEK-1 
and MEK-2) or SB203580 (P38 MAP kinase); (3) examination of whether inhibition of 
LPS-induced activation of NF-kB results in the inhibition of COX-2 expression in LPS- 
stimulated RAW 264.7 macrophages by using Z-LLF-CHO, an inhibitor o f  NF-kB; (4) 
examination of whether inhibition of both LPS-induced activation o f MAPKs and NF- 
kB results in the inhibition o f COX-2 expression in LPS-stimulated RAW 264.7 
macrophages by using PTK inhibitors such as Radicicol and Herbimycin A; (5) 
examination of whether overexpression of mutant Lyn can induce the expression of 
COX-2 in NIH/3T3 cells, which are transfected with wild type and mutant lyn DNAs.
1.2. Review of Literature
LPS treatment results in high expression o f COX-2 mRNA and protein as well 
as high production of prostaglandin E2 (PGE2) in LPS-stimulated rat alveolar
7
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macrophages (Lee et al., 1992; Chanmugam et al., 1995) and RAW 264.7 cells (Gang, 
1996). Numerous studies have shown that the mitogen-activated protein kinases 
[MAPKs; extracellular signal-regulated kinases (ERKs), P38 MAP kinase, and c-Jun N- 
terminal kinases (JNKs)], nuclear factor-kappa B (NF-kB), and Src family protein 
tyrosine kinases (PTKs) are rapidly activated in the LPS signaling pathways. In this 
review, we describe COX and the biosynthesis of prostaglandins. We also discuss 
MAPKs, Src family PTKs, and NF-kB transcription factor.
1.2.1. Cyclooygenase [COX, or Prostaglandin H (PGH) Synthase]
COX, which is also known as prostaglandin H (PGH) synthase, catalyzes the 
first committed step in the formation of PGs and TXs from arachidonic acid, which are 
released from the cell membrane phospholipids by a cytosolic phospholipase A2  
(CPLA2). The pathway of prostaglandin biosynthesis by COX from arachidonic acid is 
illustrated in Figure 1. COX is a monomeric protein having approximately a 77-78 kDa 
molecular weight and possessing two enzymatic activities: oxygenase activity and 
hydroperoxidase activity. COX generally catalyzes two sequential reactions. The first 
reaction is the formation of prostaglandin G2 (PGG2) derivatives (15-hydroperoxy-9a,
1 la-peroxido-prostaenoic acids) from two molecules of oxygen and one molecule of 
polyunsaturated fatty acids, such as 8,11,14-octadecatrienoic acid (linolenic acid, 18:3), 
5,8,11,14-eicosatetraenoic acid (arachidonic acid, AA, 20:4), or 5,8,11,14,17- 
eicosapentaenoic acid (EPA, 20:5). This bis-oxygenase activity that catalyzes PGG 
formation is also referred to as the fatty acid cyclooxygenase, or simply the 
cyclooxygenase (COX). The second reaction is a two-electron reduction of the 15- 
hydroperoxy group of PGG2  that produces the corresponding prostaglandin H2 (PGH2)
8
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STIMULUS
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Figure 1. The pathway of prostaglandin biosynthesis by COX from arachidonic acid 
(Smith and Mamett, 1991).
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derivatives (Miyamoto et al., 1976; Ohki et al., 1979). The reductive reaction is carried 
out by a hydroperoxidase activity. Monoclonal antibodies prepared against COX can 
immunoprecipitate both COX and hydroperoxydase activities (Pagels et al., 1983), 
indicating that both COX and hydroperoxidase activities are likely to be associated with 
the same protein molecules.
There are three kinds o f COX inhibitors. The first class of COX inhibitors 
inhibits the activity o f COX by reducing hydroperoxide activators or by preventing the 
interaction of hydroperoxide activators with heme. They include CN- and glutathione 
(GSH) plus GSH peroxidase (Helmer et al., 1980). The second class o f COX inhibitors 
includes some compounds with antioxidant activities. At high concentrations, they 
appear to trap free radical intermediates generated during catalysis (Helmer et al., 1980; 
Lands et al., 1982). The third class o f COX inhibitors is a large number of structurally 
diverse agents that compete kinetically with fatty acid substrates. Included in this class 
are various fatty acids, particularly polyunsaturated fatty acids (PUFAs) (Pace-Asciak et 
al., 1968) and most nonsteroidal anti-inflammatory drugs (NSAIDs) (Flower, 1974). It 
has been reported that NSAIDs have little or no effect on hydroperoxidase activities 
(Egan et al., 1980; Mizuno et al., 1982). Most NSAIDs are reversible COX inhibitors. 
However, in addition to a reversible competition with fatty acids for the active site of 
COX, some agents irreversibly inhibit COX activity. Included in this class of 
irreversible COX inhibitors are aspirin, indomethacin, flurbiprofen, and mefanamic acid 
(Smith et al., 1971; Rome et al., 1975). These agents apparently act by deleterious 
alterations in the structure o f COX (but not hydroperoxydase) active site. Aspirin 
irreversibly inhibits COX activity by acetylation of the Ser-530 in the COX active site,
10
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thereby excluding access for arachidonic acid, which is the substrate of COX (Smith,
1992). Both indomethacin and flurbiprofen irreversibly inhibit COX activity, but do not 
form covalent linkages with amino acid side chains in the COX (Stanford et al., 1977).
It has been known that a unique feature of COX is that following the conversion 
of PGG2 to PGH2 , COX is rapidly autoinactivated, leading to dramatic reduction of 
prostaglandin production (Wu et al., 1988). This suggests that stimulation of the 
biosynthesis o f prostaglandins by COX stimulated with agonists is self-limiting because 
of this rapid inactivation of COX. It also has been reported that the half-life o f COX is 
very short (t[/2<10 min), as estimated by in vitro (Wu et al., 1988) as well as in vivo 
(Fagan et al., 1986) method. Additionally, COX shows another characteristic of 
irreversible self-inactivation. It is estimated that after 1500 turnovers of product 
formation, COX is irreversibly inactivated by a yet unidentified peroxide-like molecule 
(Rossi et al., 1986; Endo et al., 1988). Therefore, rapid de novo synthesis of COX is 
required to maintain prolonged production o f prostaglandins in cells and it may be a 
most important mechanism to control prostaglandin biosynthesis (Rozengurt et al., 
1983). Based on these observations, it is possible to postulate that rapid de novo 
synthesis o f COX is assumed to be the most important step in the regulation of 
prostaglandin biosynthesis.
Although COX has been studied in detail, relatively little is known about the 
factors that control COX expression and how the controlled expression of COX in turn 
affects the production of prostaglandins. It has been demonstrated that increased COX 
activity results in increased production of prostaglandins in interleukin (IL)-la-treated 
smooth muscle cells (SMC) (Feng et al., 1993), platelet-derived growth factor (PDGF)-
11
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treated 3T3 cells (Habenicht et al., 1985; Lin et al., 1989), and LPS-treated 
macrophages (Lee et al., 1992; O’Sullivan et al., 1992; Chanmugam et al., 1995). 
Selective inhibitors of transcription and translation as well as posttranscriptional events 
are responsible for the expression o f COX by the treatment of IL-1 in human dermal 
fibroblast (Raz et al., 1989). In some studies with cycloheximide and actinomycin D, 
results have shown that the induction of COX activity involves the de novo synthesis of 
COX mRNA and protein (Wu et al., 1988; Lin et al., 1989). Fagan et al. (1986) 
reported that inhibitors of protein and RNA synthesis cause a rapid inhibition in 
prostaglandin production at the prostaglandin synthase step. It has been demonstrated 
that the treatment o f corticosteroids inhibits the production of prostaglandins by 
inhibiting the expression of COX mRNA (Bailey et a l,  1985; Bailey et al., 1988; Pash 
et al., 1988). Stimuli to induce de novo synthesis of COX mRNA and protein are 
included: PDGF (Lin et al., 1989; Habenicht et al., 1985), epithermal growth factor 
(EGF) (Pash et al., 1988), phorbol ester (Wu et al., 1988), IL-1 (Raz et al., 1988; 
O’Neill et al., 1987), IL-2 (Frasier-Scott et al., 1988), cyclic AMP (cAMP) (Kusaka et 
al., 1988), and LPS (Lee et al., 1992; Chanmugam et al., 1995; Gang, 1996).
Two isoforms of COX have been identified in eukaryotes: the constitutively 
expressed COX-1 (DeWitt et al., 1988; Merlie etal., 1988; Yokoyama et a l,  1988; 
DeWitt et al., 1990; Yokoyama et al., 1989), which is encoded by a 2.8-kilobase (kb) 
mRNA, and the mitogen-inducible COX-2 (Kujubu et al., 1991; Xie et al., 1991; 
O’Banion et al., 1992; Hla et al., 1992; Jones et al., 1993; Feng et al., 1993), which is 
encoded by a 4.0-kb mRNA. cDNAs coding for COX-1 have been cloned from ovine 
(DeWitt et al., 1988; Yokoyama et al., 1988), mouse (DeWitt et al., 1990), rat (Feng et
12
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
al., 1993; Kennedy et a l, 1993), and human (Funk et al., 1991; Hla et al., 1992; 
Yokoyama et al., 1989). cDNAs coding for COX-2 have been cloned from mouse (Xie 
et al., 1991; Kujubu et al., 1991), rat (Feng et al., 1993; Kennedy et al., 1993), and 
humans (Hla et al., 1992). COX-1 is expressed in most type of cells. In contrast, COX- 
2 is only detectable in prostate, brain, testis, and lung. COX-2 gene expression can be 
dramatically increased in some tissues during inflammation, or in fibroblasts and 
endothelial cells exposed to mitogenic stimuli (Kujubu et a l, 1992).
Xie et al. (1991) found that a mitogen-inducible COX-2 is encoded by a CEF 
(chicken embryo fibroblast)-147 cDNA and the 70-kDa polypeptide is homolous with 
about 59% identity to that of ovine, murine, and human COX. It also has been shown 
that a 4.5-kb PMA-inducible immediate early gene transcript, termed TIS10, is 
contained in PMA-treated 3T3 cells (Kujubu et a l, 1991). The murine TIS10 
polypeptide possesses significant sequence identity (about 59%) to the known COX-1, 
but it shows about 82% homologous to the chicken COX-2 polypeptide. A human 
COX-2 cDNA also has been cloned from human umbilical vein endothelial cells (Hla et 
a l,  1992). This human COX-2 cDNA encodes a polypeptide of 604 amino acids that is 
about 61% homolous to the human COX-1 polypeptide.
Structurally, COX-2 protein contains more 18 amino acids very near the C- 
terminus o f the enzyme, which is not contained in the COX-1 protein, indicating that 
COX is encoded by at least two genes that are differentially expressed and regulated in a 
variety o f cell types.
13
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1.2.2. Biosynthesis of Prostaglandins
Prostaglandins are derived from mainly arachidonic acid (20:4, n-6) or its 
precursor linoleic acid (18:2, n-6) (Willis, 1981). A process of chain elongation and 
desaturation of precursor fatty acids necessary for prostaglandin biosynthesis is 
summarized in Figure 2. In animals, this bioconversion takes place primarily in the 
liver by several stages of chain elongation and desaturation. In the n-6 series, linoleic 
acid (18:2, n-6) is desaturated to 18:3 (n-6), then elongated and desaturated to 20:3 (n-6) 
and 20:4 (n-6) which are incorporated into the cell membrane phospholipids. In the n-3 
series, linolenic acid (18:3, n-3) is desaturated to 18:4 (n-3), then elongated to 20:4 (n- 
3), and further desaturated to 20:5 (n-3), which is a relatively poor substrate for 
prostaglandin biosynthesis (Willis, 1981).
Arachidonic acid (AA) is predominant in cell membrane phospholipids. Stossel 
et al. (1974) reported that AA is the major polyunsaturated fatty acid (PUFA) in the cell 
membrane phospholipids of human monocytes and lymphocytes and comprises about 
20% of the total fatty acids. For the prostaglandin biosynthesis, AA should be 
hydrolyzed by specific phospholipases from the cell membrane phospholipids (Brown et 
al., 1988). After AA is released by phospholipases (e.g. cPLA2) from the cell 
membrane phospholipids, AA is converted by the COX and LOX pathways to various 
eicosanoids. These pathways are usually called as the AA cascades. These AA 
cascades are illustrated in Figure 3. The products of the COX pathway include 
thromboxanes (TXs), prostacyclins (PGIs), and prostaglandins (PGs). Among PGs, 
PGEi and PGE2 are implicated in the inhibition of various aspects of immune response,
14
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Figure 2. A process of chain elongation and desaturation of precursor fatty acids 
for prostaglandin biosynthesis (Hwang, 1989).
15
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Dietary n-6 polyunsaturated fatty acids 
Cell membrane phospholipids
Phospholipases (eg, CPLA2) 
Free arachidonic acid
Lipoxygenase (LOX) pathway
Hydroperoxyeico- 
satetraenoic acid 
(HPETE)
Cyclooxygenase (COX) pathway
I
Endoperoxide 
intermediates 
(PGG2, PGH2)
Hydroxyeicosa- 
tetraenoic acid 
(HETE)
LeuRotriens
(LTs)
1 I
Prostacyclins
(PGI2)
Prostaglandin Es Thromboxanes 
(PGEs) (TXs)
Figure 3. The arachidonic acid cascades (modified from Smith, 1992).
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such as lymphocyte proliferation (Goodwin et al., 1977), macrophage collagenase 
synthesis (Wahl et al., 1977), and natural killer cell activity (Brunda et al., 1980). 
Therefore, PGs may play a role as a mediator of a feedback mechanism for controlling 
some aspects o f cell mediated immune responses (Gordon et al., 1976). TXs act as 
potent platelet aggregators as well as important mediators in muscle contraction and 
lipolysis (Hamberg et al., 1974). In contrast, LOX oxygenates AA to make the 
hydroperoxide intermediate hydroperoxy-5, 8,12,14-eicosatetraenoic acid (HPETE), 
which is further metabolized to various hydroxyeicosatetraenoic acids (HETEs) and 
leukotriens (LTs). LTs have important pro-inflammatory effects and play a crucial role 
in hypersensitivity reactions (Lewis et al., 1980) and bronchospasms in allergic asthma 
(Dahlen etal., 1983).
1.2.3. Mitogen-Activated Protein Kinases (MAPKs)
Protein phosphorylation plays a critical role in regulating many cellular 
processes in eukaryotes. In particular, protein phosphorylation is a major event of signal 
transduction pathways. Processes that are reversibly controlled by protein 
phosphorylation require not only protein kinases (PKs) but also protein phosphatases 
(PPs). Target proteins are phosphorylated at specific sites by one or more PKs, and 
these phosphates are removed by specific PPs. In principle, changing the activity o f the 
cognate PK or PP or both can control the degree of phosphorylation at specific sites 
(Hunter, 1995). The latest estimate is that there are as many as 2,000 conventional PK 
genes in human (Hunter, 1994). It also has been estimated that humans could have as 
many as 1,000 PP genes (Hunter, 1995).
17
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Among PKs, mitogen-activated protein kinases (MAPKs) are sereine/threonine 
kinases that are rapidly activated in cells stimulated by several extracellular agents. 
MAPKs play important roles in many intracellular signal transduction pathways that 
lead to gene expression (Karin et al., 1995). The MAPK pathway is known to be a 
conserved eukaryotic signaling pathway that converts receptor signals into a variety of 
outputs (Davis, 1994). The MAPK pathway is extensively used for the transcytoplasmic 
signaling to the nucleus, where transcription of specific genes is induced through 
phosphorylation and activation of many transcription factors catalyzed by activated 
MAPKs (Hunter, 1995). The general MAPKs signaling pathway from extracellular 
stimuli to the nucleus is displayed in Figure 4.
In general, a variety of extracellular stimuli lead to the formation of membrane- 
associated signaling complexes that deliver the signal via Ras to a protein kinase 
network involving the Raf-1 kinase, the MAPK activator MEK (or MAPKK), and 
MAPKs (Blenis, 1993). Activated Raf-1 in turn phosphorylates and activates MEK in 
vivo and in vitro (Howe et al. 1992; Kyriakis et al., 1992). These kinases are arranged 
in a linear cascade, in which Raf-1 phosphorylates and activates MEK, which in turn 
phosphorylates and activates MAPKs. Activated MAPKs deliver the signal to the 
nucleus, where they phosphorylate and activate specific transcriptional factors capable 
o f inducing specific immediate early gene expressions (Gille et al., 1992; Hipskind et 
al., 1994; Janknecht et al., 1993). There are three main classes of MAP kinase 
recognized in mammals. In addition to the classic MAP kinase, also known as the 
extracellular signal-regulated protein kinase (ERK), two other distinct classes of MAP 
kinases have been identified: the c-junN-tenninal kinase/stress-activated protein
18
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Figure 4. The general MAPKs signaling pathway (Seger, 1996).
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kinases (JNKs/SAPKs) (Cooper, 1994; Kyriakis et a l, 1994; Sanchez et al., 1994; 
Derijard et al., 1995; Lin et al., 1995; Gupta et al., 1996) and the P38/reactivating 
kinases (RK)/cytokine-suppressive binding protein (CSBP)/HOGl MAP kinase 
(Freshney et al., 1994; Han et al., 1994; Lee et al., 1994; Rouse et al., 1994).
All these MAP kinases are activated by dual phosphorylation of threonine 
(Thr)/tyrosine (Tyr) residues in the activation loop catalyzed by specific MAP kinase 
kinases (MEK1, MEK2, SEK1/MKK4/JNKK, MKK3, MKK6/MEK6) (Cooper etal., 
1994; Han et al., 1996; Cano et al., 1995; Lin et al., 1995; Derijard et al., 1995; 
Moriguchi et al., 1996; Stein et al., 1996). The activated MAP kinases in turn 
phosphorylate various intracellular target proteins at Ser/Thr-Pro sequence. Although 
these MAP kinases have similar primary structures, activation mechanisms, and similar 
minimal consensus sequences for substrate recognition, these distinct classes of MAPK. 
are differentially activated by different extracellular stimuli, and these activated MAPKs 
in turn activate shared or specific downstream targets, such as many transcription 
factors (Fukunaga et al., 1997).
I.2.3.I. ERK/MAP Kinases
The first o f the ERK/MAP kinases to be cloned was ERK-1 (the same as MAPK- 
1) and ERK-2 (the same as MAPK-2) (Boulton et al., 1991a; Gotoh et al., 1991). Other 
related ERK/MAP kinases have been identified including: two ERK-3 isoforms 
(Gonzalez et al., 1992; Zhu et al., 1994), ERK-4 (Boulton et al., 1991b), ERK-5 (Zhou 
et a l, 1995; Kato et a l,  1997; English et a l, 1998), ERK-6, and ERK-7. These 
ERK/MAP kinases are activated in cells stimulated by various extracellular stimuli, such 
as phorbol esters, which activate protein kinase C (PKC) and by growth factors, such as
20
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epithermal growth factor (EGF) and platelet-derived growth factor (PDGF), which 
activate receptor protein-tyrosine kinases. These receptor protein-tyrosine kinases 
activated by growth factors sequentially leads to the activation of Ras, Raf, MEK, and 
ERK-1 and ERK-2 MAP kinases (Davis, 1993).
The ERK-1 and ERK-2 are activated by dual phosphorylation at Thr and Tyr 
residues by MEK-1 and MEK-2, respectively (Crews et al., 1992; Ahn et al., 1992). 
Several substrate proteins identified as physiological targets for ERK MAP kinases 
include the 90 kDa ribosomal S6 protein kinase (called RSK), cytosolic phospholipase 
A2 (called CPLA2), and transcriptional factors, such as Elk-1 (Davis, 1993; Janknecht et 
al., 1993; Marais et al., 1993; Gille et al., 1995). It has been recently demonstrated that 
three p90 ribosomal S6 kinase (RSK) isozymes (RSK1, RSK2, and RSK3) interact with 
extracellular signal-regulated kinase (ERK) but not c-Jun-NH2-kinase (JNK) or p38 
mitogen-activated protein kinase (MAPK) (Smith et al., 1999). These observations 
suggest that activated ERK MAPKs play a role in gene expression.
1.23.2. P38/HOG1 MAP Kinase (or RK/CSBP)
P38/HOG1 MAP kinases are stress-responsive MAP kinases. In yeast, HOG1 is 
necessary for growth in conditions o f high osmolarity, but not required for normal 
growth (Brewster et al., 1993). In mammalian cells, P38 MAP kinase, a HOG1 
homologue, responds to extracellular stimuli, such as heat, chemical stress, high 
osmolarity, LPS (Han etal., 1994), andIL-1 (Freshney etal., 1994). BothHOGl and 
P38 MAP kinase share the parallel MAPKK-like activation motif Thr-Gly-Tyr rather 
than Thr-Glu-Tyr found in ERK-1 and ERK-2 or Thr-Pro-Tyr found in JNKs, suggesting 
activation by an alternative MAPKK (Lee et al., 1994). P38 has been implicated to be a
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crucial MAPK. in the pro-inflammatory cytokine pathway. Four members o f P38 
MAPKs have been identified so far. They include p38, p38 beta, p38 gamma (Li et al.,
1996), and p38 delta (Jiang et al., 1997). MKK3 and MKK6 are upstream activators o f 
P38 MAPK (Raingeaud et a l,  1996). Recently Enslen el a l,  (1998) also reported that 
the MAP kinase kinases MKK3 and MKK6 selectively activate p38 mitogen-activated 
protein kinase isoforms, such as p38 alpha, p38 beta 2, and p38 gamma, suggesting the 
MKK3 and MKK6 signaling pathways are coupled to separate, but overlapping groups 
of p38 MAPKs. P38 MAP kinases are weakly activated by mitogens, but strongly 
activated by cell stresses, bacterial LPS, IL-1, and TNF-cc (Freshney et al., 1994; Lee et 
a l,  1994; Rouse et a l,  1994; Raingeaud et al., 1995). Activated P38 MAP kinase in 
turn phosphorylates cPLA2 (Kramer et al., 1995; Borsch-Haubold et al., 1997) and some 
transcriptional factors including ATF2 (Raingeaud etal., 1995) and Elk-1 (Raingeaud et 
al., 1996). It has been demonstrated that the pathways of p38 MAPK and ERK are 
cooperative for the activation of NF-kB in TNF signaling pathway (Vanden Berghe et 
al., 1998). Han et a l, (1997) also demonstrated that a possible link between the p38 
MAPK pathway and a member of the myocyte-enhancer factor 2 (MEF2) group of 
transcription factors, which are involved in inflammation. They indicated the increasing 
transactivating activity of MEF2C by activated p38 MAPK in LPS signaling pathway. 
These observations suggest that activated P38 MAPK and JNKs play a role in gene 
expression.
I.2.3.3. JNKs/SAPKs
JNKs/S APKs are stress-responsive MAP kinases. These are activated by 
ultraviolet (UV) irradiation and osmotic stress, and activated JNKs phosphorylate a
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transcription factor c-Jun (Derijard et al., 1994; Kyriakis et al., 1994; Pulverer et al.,
1991). MKK7 is an upstream activator of JNKs (Toumier et al., 1997; Foltz et al., 
1998). Activated JNK binds to the c-Jun transactivation domain and phosphorylates 
both Ser-63 and Ser-73 in the c-Jun and activates the c-Jun (Hibi et al., 1993). Two 
polypeptides (46 kDa and 54 kDa) exhibiting JNK activity have been identified by 
biochemical characterization (Hibi et al., 1993). Although the module o f regulation is 
similar, the 46 kDa polypeptide has a higher affinity for binding to c-Jun than the 54 kDa 
polypeptide (Hibi et al., 1993). Under UV irradiation, both forms of JNK (JNK-46 and 
JNK-54) are rapidly and potently activated (Devary et al., 1991; Hibi et al., 1993).
Similar to ERK-1 and ERK-2, JNK-1 requires dual phosphorylation at both Thr 
and Tyr for activation. In structure, however, the dual phosphorylation site motif present 
in JNK-1 (Thr-Pro-Tyr) is distinct from that located in ERKs (Thr-Glu-Tyr). These Thr 
and Tyr residues are also conserved in JNK-1 and mutations of these residues inhibited 
the phosphorylation and activation of JNK-1 induced by UV treatment (Derijard et al., 
1994). The structure of JNK-1 revealed homology to ERK-1 and ERK-2 (Boulton et al., 
1991) by comparison of the deduced structure o f JNK-1 with ERK-1 and ERK-2 using 
the GenBank data base (Blast Fileserver, National Center of Biotechnology Information) 
(Boulton et al., 1990,1991). It has been observed that there is sequence homology 
between JNK-1 and the yeast HOG1 MAP kinase (Brewster et al., 1993). JNK also 
plays an important role in the activation o f  the activating transcription factor 2 (ATF 2) 
(Livingstone et al., 1995; van Dam et al., 1995; Botteron and Dobbelaere, 1998) and 
another transcription factor, the activator protein-1 (AP-1) (Botteron and Dobbelaere, 
1998), suggesting the involvement of JNK on the gene expression.
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1.2.4. Src Protein Tyrosine Kinases
The Src family kinases, which are named after the src oncogene of Rous 
sarcoma virus, are a type of non-receptor protein tyrosine kinases (PTKs) that play 
important roles in eukaryotic signal transduction (Sicheri et al., 1997; Sicheri and 
Kuriyan, 1997). So far, 9 Src family PTKs (Src, Lyn, Fgr, Hck, Fyn, Yes, Lck, Blk, and 
Yrk) have been identified (Brown et al., 1996).
The Src family members share a common regulatory mechanism, but differ in 
cellular expression and localization. The Src, Yes, Fyn, and Lyn are expressed in 
various cell types, whereas the Lck, Hck, Fgr, and Blk are expressed primarily in 
hemopoietic cells (Bolen et al., 1992). Hck is expressed primarily in lymphoid and 
myeloid cells (Quintrell et al., 1987; Zeigler et al., 1988). Several members of the Src 
family kinases are usually present in each cell type.
The Src family kinases are highly homologous in structure. The general 
structure of the Src family kinases is shown in Figure 5. They all contain an N-terminal 
myristylation domain, Src homology 2 (SH2) and Src homology 3 (SH3) domain, a 
protein kinase domain (also designated as a catalytic domain), and a C-terminal 
regulatory domain. The sequences necessary for fatty acylation (myristylation and 
palmitylation) and stable membrane association are located at the amino terminus o f the 
Src family kinases. Myristylation and palmitylation help the Src family kinases target to 
the cell membranes. For example, a myristic acid is covalently bound to a common 
glycine-2 by an amide linkage in most Src family kinases except Src kinase (Resh,
1990). Adjacent to this small domain is the 50- to 80- amino acids “unique” domain
24
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Figure 5. The general structure of the Src family kinases (Bolen, et al., 1992).
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where the amino acid sequences between the Src family kinases diverge most 
dramatically. The region of the Src family kinase extending from about 90- to 250- 
amino acids represent sequences that share identity with other non-receptor protein 
tyrosine kinases as well as other classes of cellular regulatory and structural proteins. 
This region can be subdivided into the roughly 50-amino acids SH3 domain and 
approximately 100-amino acids SH2 domain (Bolen et a l, 1992). The majority of the 
C-terminal half of the Src kinases represents the catalytic domain, which is the region of 
highest Src family sequence identity. Two important features in the catalytic domain 
include the ATP binding site centered on a common lysine residue and the 
autophosphorylation site on the tyrosine residue. The last 15- to 17-amino acids are 
termed the C-terminal regulatory domain because deletion of these sequences or site- 
specific mutation of the tyrosine residue in the C-terminal regulatory domain to another 
amino acid (e.g. phenylalanine) significantly activates the enzymatic function of Src 
kinases. Such alterations render Src family kinases nonregulatable, and when expressed 
in an appropriate cell type, these mutants are highly oncogenic (Bolen et a l, 1992).
Two major consensus tyrosine phosphorylation sites have been identified in Src 
family kinases: (1) the autophosphorylation site on tyrosine residue in the catalytic 
domain and (2) the phosphorylation site on tyrosine residue in the C-terminal regulatory 
domain. Autophosphorylation on the tyrosine residue in the catalytic domain correlates 
with the activation of Src kinase activity, while phosphorylation on tyrosine residue in 
the C-terminal regulatory domain suppresses its kinase activity (Cooper et a l, 1986).
As noted previously, the highly conserved regulatory apparatus o f the Src family 
members consists of two peptide-binding modules, the Src homology domains SH2 and
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SH3. These modules bind to targets containing phosphotyrosines and polyproline type 
II helices, respectively, and mediate the formation o f protein-protein complexes during 
signaling (Pawson et al., 1995). It is likely that interaction between the SH2 domain 
and a C-terminal phosphotyrosine residue in the Src kinases results in a decrease of 
catalytic activity of Src kinases, with additional inhibitory interactions provided by the 
SH3 domain.
The inhibitory phosphorylation at Tyr-527 in the C-terminal regulatory domain 
of c-Src is mediated by a distinct tyrosine kinase, c-Src kinase (Csk) (Nada et al., 1991). 
It is now clear that phosphorylation of Tyr-527 by Csk inhibits Src catalytic activity by 
creating an intramolecular binding site for the Src SH2 domain (Roussel et al., 1991).
In contrast, autophosphorylation at another tyrosine residue (Tyr-416 in c-Src), located 
within the ‘activation segment’ o f the catalytic domain, is required for its catalytic 
activity (Brown et al., 1996).
The catalytic domain of the Src kinases alone is functional as a tyrosine kinase, 
but the Src SH2 and SH3 domains are required for full biological activity. Certain 
mutations in these domains lead to host cell-dependent phenotypes, indicating that they 
play a dual role in the Src kinases (Brown et al., 1996). Several lines o f evidence also 
suggest that this regulation is governed by an intramolecular interaction between the 
phosphorylated C-terminal tyrosine and the SH2 domain that somehow stabilizes the 
inactive conformation of the kinases. The classically characterized v-src oncogene from 
avian retroviruses encodes a constitutively active kinase (Takeya et al., 1983). Mutation 
o f  the conserved tyrosine (Tyr-527 in avian c-Src) to a phenylalalnine also creates an 
active oncogenic protein (Hunter, 1987). It has been shown that COX is persistently
27
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
induced in p60 v'src (Tyr-527 at the C-terminal regulatory domain in c-Src was replaced 
with a phenylalanine)-transformed 3T3 fibroblasts (Han et al., 1990). It has been 
reported that one of the cDNAs induced in chicken embryo fibroblasts (CEFs) by 
activation o f a temperature-sensitive w-src oncogene encodes a prostaglandin synthase 
(PGS) (Simmons et al., 1991; Xie et al., 1991). p60 v'src induces prostaglandin 
synthase-2 (PGS-2, COX-2) gene expression by activation of the c-jun N-terminal 
kinase (JNK) and the c-jun transcription factor (Xie et al., 1995). Numerous studies 
have shown that gene expression can be induced by p60 v‘src through different c/s-acting 
regulatory elements, including AP-1 (Birchenall-Roberts et al., 1990), the serum 
response element (SRE) (Qureshi et al., 1991), and a unique src-responsive element 
(Dehbi et al., 1992). It has been demonstrated that the induction of TIS10/PGS2 
prostaglandin synthase gene expression by v-Src is mediated by an ATF/CRE 
transcription response element (Xie et al., 1994). These observations suggest a critical 
role of C-terminal tyrosine residue in regulating Src kinase activity and also imply that 
many immediate early gene expressions including COX-2 gene can be induced by a 
single amino acid change in another Src kinases.
While studying the structure and expression of \-yes, a clone, which is termed 
Ick/yes-related novel tyrosine kinase (lyn), was isolated in human (Yamanashi et al., 
1987). This human lyn clone contains an open reading frame (ORF) which codes for a 
mature Lyn protein with 512 amino acids (Rider et al., 1994). Subsequently the full- 
length murine homologue of lyn was isolated (lyn A), as well as a smaller form (lyn B) 
lacking 24-44 amino acids which was otherwise identical to the larger form (Yi et al.,
1991). Both forms of lyn encoding p53 and p56 polypeptides are derived from a single
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gene by alternative splicing o f the RNA transcripts (Stanley et a l,  1991). Other 
alternatively spliced RNAs in the Src family kinases, such as src and hck (gene 
encoding hematopoietic cell kinase), are differentially expressed in various tissues or 
subcellular fractions (Levy et a l,  1987; Lock et a l, 1991). However, the two isoforms 
of murine Lyn are coexpressed in all identified tissues and both bind the B-cell IgM 
receptor (Stanley et a l, 1991).
Yamanashi et a l  (1991) suggested that Lyn might be involved in the regulation 
of the immune response. Han et al. (1993) reported that initial interaction o f LPS with 
monocytes and macrophages involves a LPS-binding protein (LBP) that binds to LPS 
and a glycosylphosphatidylinositol-anchored cell surface glycoprotein, CD 14 receptor.
It has been shown that Lynp53/56 was co-immunoprecipitated with CD 14 in human 
monocytes (Stefanova et al., 1993). These observations suggest a functional role of Lyn 
kinase as the immediate upstream activator in the LPS/CD14-mediated signal 
transduction pathways in monocytes and macrophages that lead to COX-2 expression.
1.2.5. Nuclear Factor-kappa B (NF-kB)
It has been reported that NF-kB induces the expression of many effector proteins 
involved in immune response, inflammation, and the transcription of numerous genes 
encoding cytokines, or growth factors (Siebenlist et a l, 1994). The transcriptional 
regulation of adhesion molecules, enzymes, and cytokines involved in chronic 
inflammatory diseases is controlled by the transcription factor NF-kB (Barnes et a l,
1997).
The active NF-kB that binds to DNA in dimeric complexes is composed of 
various combinations of members o f the Rel/NF-kB family (Siebenlist et a l,  1994).
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The Rel/NF-kB family is distinguished by the presence of a so-called Rel homology 
domain (RHD) of about 300 amino acids in length, which shows 35-61% identity 
between this family members (Bours et al., 1992; Ryseck et al., 1992). The RHD 
determines DNA binding to kB elements, dimerization with identical or other members 
o f the family, as well as interaction with the IkB family of proteins (Siebenlist et a l, 
1994).
The Rel/NF-kB family members can be divided into two classes. One is the 
pl05 and plOO precursor proteins, which are processed proteolytically to the mature p50 
and p52 forms, respectively (Ghosh et a l, 1990; Schmid et a l, 1991). The other class is 
the Rel (c-Rel), v-Rel, RelA (p65), and RelB proteins (Stephens et al., 1983; Nolan et 
a l,  1991; Ruben et a l,  1991; Ryseck et a l, 1992). The members of the Rel/NF-kB 
family of proteins can form almost all theoretically possible homo- and heterodimes, 
making many complexes through combinatorial mixing (Siebenlist et al., 1994). 
Dimerization is necessary for DNA binding (Bressler et a l, 1993). Thep50/RelA 
(p50/p65) complex is usually the most abundant dimeric complex and is present in 
essentially most type of cells. Among the other possible dimeric complexes, 
homodimers o f RelA or Rel or RelA/Rel heterodimers are only formed at very low 
levels. Such complexes may, nevertheless, play unique and critical roles on specific 
promoters (Hansen et al., 1992; Nakayama et al., 1992; Ganchi et a l, 1993; Kunsch and 
Rosen, 1993). The various dimeric complexes have a different preference for certain kB 
sites, transactivation potentials, kinetics o f nuclear translocation, and levels of 
expression in tissues (Siebenlist et al., 1994). In response to extracellular activation, the
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nearly ubiquitously expressed p50/RelA is likely to be rapidly translocated to the 
nucleus (Molitor et al., 1990), where gene transcription occurs.
The highly conserved RHD, which is also the only region shared by all members 
of this family, plays a significant role for DNA binding, dimerization, nuclear 
translocation, and binding to IkB inhibitors (Siebenlist et al., 1994). A short stretch of 
amino acid domain (the so-called RXXRXRXXC motif) in RHD contacts DNA directly 
(Kumar et al., 1992, 1993). Since its oxidation interferes with DNA binding, the 
cysteine residue within this motif should be in a reduced state (Toledano and Leonard, 
1991; Kumar etal., 1992; Mattews etal., 1992; Hayashi etal., 1993). A second region 
about 100 amino acids further C-terminal to the RHD is significant because of possible 
DNA binding (Bressler et al., 1993). The C-terminal end of the RHD possesses 
conserved and positively charged amino acids, which function as a nuclear localization 
sequence (NLS) and possibly interact with the inhibitory IkB proteins (Blank et al., 
1991; Beg et al., 1992; Henkel et al., 1992).
Different NF-kB dimers have different binding affinities to certain kB sites 
(Urban and Baeuerle, 1990; Bours et al., 1992b; Perkins et al., 1992; Franzoso et al., 
1993). Most kB elements are somewhat palindromic, which gives these elements a 
directional sense relative to the transcriptional start site (Urban and Baeuerle, 1990,
1991).
The IkB family of proteins includes DcB-a, EkB-P, the precursor protein p i 05 
and plOO, IkB-y, and Bcl-3. IkB-a and IkB-P have a  difference in molecular weights 
(IkB-cc is 37 kDa and IkB-p is 43 kDa) (Zabel and Baeuerle, 1990). Based on lack of
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immunological cross-reactivity, and a difference in molecular weights, it is suggested 
that IkB-p may be encoded by a separate gene from IkB-a (Siebenlist et al., 1994).
All members of the IkB family have a partially conserved domain that contains 
six to eight ankyrin motifs, each 33 amino acids in length (Schmitz et al., 1991; Blank 
et al., 1992; Nolan and Baltimore, 1992). It has been believed that the ankyrin motifs in 
this IkB family regulate NF-kB activity (Kieran et al., 1990) by inhibiting nuclear 
translocation and DNA binding of Rel/NF-kB complexes. Among the IkB family, IkB- 
a  interacts with and shields the nuclear localization signal (NLS) located at the C- 
terminal end of the RHD domain of NF-kB (Beg et al., 1992; Ganchi et al., 1992; 
Henkel et al., 1992). Hatada et al. (1992,1993) reported that IkB-a shields the 
positively charged NLSs of both subunits of all dimeric NF-kB complexes, suggesting 
that a short, negatively charged region of IkB-a located adjacent to the most C-terminal 
(sixth) ankyrin motif may be critical.
Activation of NF-kB from cytoplasmic pools correlates with proteolytic 
degradation o f the inhibitory IkB-a protein. An observation that has been confirmed in 
many laboratories is that almost complete degradation o f IkB-a protein occurs within 
minutes following stimulation with extracellular stimuli including TNF-a or PMA (Beg 
etal., 1993; Brown etal., 1993; Sunef al., 1993; Henkel etal., 1993; Read etal., 1994). 
In addition, a post-translational phosphorylation o f IkB-a is required for the degradation 
oflkB -a (Beg etal., 1993; Brown etal., 1993; Cordl eeta l., 1993; Sun etal., 1993).
The phosphorylated form of IkB-a is transiently and shortly detected as a protein 
showing slightly retarded electrophoretic mobility after stimulation of cells. As IkB-a
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degradation occurs, NF-kB becomes active and translocates to the nucleus to induce 
specific gene transcription (Brown et al., 1993; Sun et al., 1993). The molecular 
mechanisms of NF-kB activation by the degradation of IkB-a are displayed in Figure 6.
Free and uncomplexed IkB-a is unstable in cells, whereas complexed IkB-a is 
stable in cells. It has been indicated that the phosphorylation of IkB-a releases the 
inhibitor from NF-kB, thereby leaving it unprotected from active proteases, which then 
degrade the free form of IkB-a (Beg et al., 1993; Brown et al., 1993; Sun et al., 1993). 
This observation is based on early reports indicating that several kinases activate IkB-a- 
bound NF-kB in vitro and phosphorylate and inactivate partially purified IkB-a 
(Shirakawa and Mizel, 1989; Ghosh and Baltimore, 1990).
The kinase(s) directly responsible for mediating signal-dependent 
phosphorylation of IkB-a have been reported. Li and Sedivy (1993) reported that IkB-a 
could be phosphorylated by Raf in vitro. Constitutively active NF-kB is detected in 
cells transfected with active forms of Raf. However, cells that overexpress dominant 
negative forms of Raf did not contain active NF-kB upon exposure to TNF-a, serum, 
PMA, or UV irradiation ( Devary et al., 1993; Finco and Baldwin, 1993; Li and Sedivy, 
1993). Raf may act as an IkB-a kinase (IKK) through a direct physical interaction 
between Raf and IkB-a by using a yeast two-hybrid analysis in which genes for both 
proteins were introduced in cells (Li and Sedivy, 1993). Consistent with a role o f NF- 
kB in a defensive response, the pro-inflammatory cytokines such as TNF-a, TNF-P, and 
IL-1 are potent activators of NF-kB in most type of cells (Osbom et al., 1989; Messer et 
al., 1990). For example, TNF-a-induced activation of NF-kB is blocked by
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Figure 6. The molecular mechanism of NF-kB activation (Bames and Karin, 1997).
34
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
overexpression of dominant negative Raf mutant (Devary et al., 1993; Finco and 
Baldwin, 1993). Since MAPKs, a downstream effector of Raf, are activated by TNF 
treatment (Saklatvala et al., 1993), Raf may lie on this pathway, supporting the previous 
hypothesis that Raf may be a possible kinase that phosphorylates IkB-a. Other studies 
suggest an essential role for protein kinase C (PKC) zeta in TNF-a signaling pathway 
which leads to activation of NF-kB. This view is based on that active NF-kB is detected 
by overexpression of constitutively active PKC zeta protein in NIH/3T3 cells (Diaz- 
Meco et al., 1993).
Reactive oxygen intermediates (ROIs) play a role as a common and critical 
messenger molecule for various activating signals (Schreck et al., 1992a, 1992b). This 
observation is based on that a variety of antioxidants block NF-kB activation. For 
example, pyrolidinedithiocarbamate (PDTC), an antioxidant, blocks the degradation of 
IkB-a induced by the treatment with TNF-a and PMA in some Jurkat T cell lines (Beg 
et al., 1993; Henkel et al., 1993; Sun et al., 1993). Evidence showing elevated cellular 
levels o f ROIs in response to TNF-a, IL-1, PMA, LPS, UV light, and gamma-irradiation 
supports the possible involvement of ROIs as common messenger molecules (Schreck et 
al., 1992a,1992b; Geng etal., 1993, Schieven et a l,  1993). Among ROIs such as 
hydrogen peroxide, hydroxyl radicals, superoxide, and singlet oxygen, only hydrogen 
peroxide treatment results in activation of NF-kB in cells (Schreck et al., 1991,1992a), 
suggesting that peroxides may play a critical role in the NF-kB signaling cascades. It 
also has been shown that the inhibitors of PTKs block NF-kB activation following 
gamma-irradiation, a stimulant that is believed to act primarily through the immediate 
generation of ROIs (Schieven et al., 1993). It is suggested that PTKs might function
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prior to the generation of ROIs (Siebenlist et al., 1994). Despite these observations, a 
direct role of ROIs in NF-kB activating signaling mechanisms has not been 
demonstrated.
Mitogenic stimuli are believed to activate NF-kB. Baldwin et al. (1991) 
demonstrated that activation of NF-kB was transiently induced by serum stimulation in 
fibroblast cultures that were grown in the absence o f serum. The active NF-kB was 
detected in Human immunodeficiency virus (HlV)-infected monocytic cells (Bachelerie 
et al., 1991; Paya et al., 1992). The treatment of okadaic acid and calyculin A, 
inhibitors of phosphatases 1A and 2 A, results in NF-kB activation (Thevenin et al., 
1990; Menon et al., 1993, 1995), suggesting the possible involvement of a negatively 
acting phosphatase in the signal transduction to IkB-a.
High levels of endogenous IkB-a mRNA were detected in cells transfected with 
transactivating NF-kB subunits (Brown etal., 1993; Scott etal., 1993; Sun etal., 1993; 
Read et al., 1994). It has been verified that the IkB-a promoter possesses kB binding 
sites, depending on transcription of IkB-a gene by NF-kB (de Martin et al., 1993; Chiao 
et al., 1994). The expression o f IkB-a, which presumably is destined to restore the 
inhibited state, is regulated by transactivating NF-kB dimers (Brown etal., 1993).
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CHAPTER 2 
MATERIALS AND METHODS
2.1. Reagents
Preparations of LPS from E.coli 0111 :B4 strain were purchased from Difco 
Laboratories Co. (Grand Island, NY). Mouse monoclonal anti-phosphotyrosine 
antibody (4G10) was purchased from Upstate Biotechnology, Inc. (UBI, Lake Placid, 
NY). Rabbit polyclonal anti-ERK-2, anti-JNK-1, and anti-P38 antibodies were 
purchased from Santa Cruz Biotech. (Santa Cruz, CA). Rabbit polyclonal anti-P38 
antibody was a gift from Dr. R. J. Ulevitch (The Scripps Research Institute, La Jolla, 
CA). Myelin Basic Protein (MBP) was purchased from GIBCO-BRL (Grand Island, 
NY). Rabbit muscle enolase was purchased from Sigma (St. Louis, MO). E.coli 
bacteria containing GST-ATF2 fusion protein was obtained from Dr. R. J. Davis 
(Program in Molecular Medicine and Howard Hughes Medical Institutes, University of 
Massachusetts Medical School, Worcester, MA). Goat anti-mouse and anti-rabbit 
immunoglobulin G (IgG) antibodies conjugated to horseradish peroxidase were 
purchased from Amersham Corp. (Arlington Heights, IL). Enhanced 
chemiluminescence (ECL) western blotting detection reagent and [y-32P] adenosine 5’- 
triphosphate (ATP) were purchased from Amersham Corp. Polyvinylidene difluoride 
(PVDF) transfer membrane was purchased from Millipore (Bedford, MA). Arachidonic 
acid was purchased from Nu-Chek (Eslyan, MN). Radicicol (an inhibitor of p60src) was 
provided by Dr. H. J. Kwon and Dr. T. Beppu (Dept, o f Biotechnology, Tokyo Univ., 
Japan). Z-LLF-CHO (an inhibitor o f BcBa degradation) was provided by Dr. F. 
Mercurio (Signal Pharmaceuticals). PD98059 (an inhibitor of MEK-1 and MEK-2) was
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obtained from Dr. A. Saltiel (Parke-Davis Pharmaceuticals). SB203580 (an inhibitor of 
P38) was obtained from Dr. P. Young (SmithKline Beecham Pharmaceuticals). An 
RPAII™ kit used for ribonuclease protection assay was purchased from Ambion Inc. 
(Austin, Texas). Sequenase™ Quick-Denature™ Plasmid Sequencing Kit was 
purchased from United States Biochemical (USB, Cleveland, OH). Phoenix (<DNX)- 
amphotropic cells (a ONX helper-free retrovirus producer line) were provided by Dr. G. 
P. Nolan (Dept, of Molecular Pharmacology and Microbiology and Immunology, 
Stanford University School of Medicine, Stanford, CA). pBPSTRl retroviral vector 
was provided by Dr. S. A. Reeves (Molecular Neuro-Oncology Laboratory, 
Massachusetts General Hospital-East, Charlestown, MA). Human lyn cDNAs were 
subcloned in pBPSTRl retroviral vector with modification by Dr. M. Awad, a previous 
post-doctorate in the laboratory of Dr. D. Hwang (Lab. of Prostaglandin Metabolism, 
Pennington Biomedical Research Center, LSU, Baton Rouge, LA).
2.2. Cell Culture
RAW 264.7 cells (an Abelson virus-transformed murine macrophage cell line, 
ATCC TIB-71) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
GIBCO-BRL) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, 
Intergen) and 1% (v/v) antibiotics (penicillin/streptomycin, Sigma) at 37° C in 5% 
CCVair mixtures. Before stimulation, 5 x 106or 10 x 106 of RAW 264.7 cells were 
plated into a 60-mm or 100-mm dish (Coming) in 5 ml or 10 ml of DMEM 
containinglO% (v/v) heat-inactivated fetal bovine serum (FBS) and 1% (v/v) antibiotics 
(penicillin/streptomycin). Cells were then grown for 18 hours to allow the number of 
cells to approximately double. After 18 hours, the culture media was removed and cells
38
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
were washed with DMEM containing 1% antibiotics (Penicillin/Streptomycin). After 
washing, cells were pretreated or treated with the appropriate agents for different time 
periods.
To examine whether the activation of MAPKs alone is sufficient to induce the 
expression of COX-2, known activators of MAPKs, such as PMA, sorbitol, H2O2 , or 
combinations of these factors (PMA plus sorbitol or PMA plus H2O2) were used. For 
the activation of MAPKs, RAW 264.7 cells were treated with LPS (1 pg/ml), PMA (100 
nM), sorbitol (0.4 M), H2O2 (1 mM),or PMA (100 nM) plus sorbitol (0.4 M) and PMA 
(100 nM) plus H2O2 (1 mM) for 30 minutes. For the expression of COX-2 mRNA and 
protein, RAW 264.7 cells were treated with LPS (1 pg/ml), PMA (100 nM), sorbitol 
(0.4 M), H2O2 (1 mM),or PMA (100 nM) plus sorbitol (0.4 M) and PMA (100 nM) plus 
H2O2 (1 mM) for 4 hours and 8 hours, respectively.
To examine whether inhibition of LPS-induced activation of MAPKs 
(particularly ERK-1, ERK-2, or P38 MAP kinase) is involved in the regulation of COX- 
2 expression, the inhibitors o f MAPKs, PD98059 and SB203580, were used. First, for 
the inhibition of ERK-1 and ERK-2, RAW 264.7 cells were pretreated with PD98059 in 
different concentrations (0,1,10, 50, 100, and 200 pM) for 1 hour in the absence of 
LPS. After pretreatment, RAW 264.7 cells were washed with DMEM containing 1% 
antibiotics (Penicillin/Streptomycin) three times. After washing, RAW 264.7 cells were 
treated with LPS (1 pg/ml) plus PD98059 in the same concentrations used in 
pretreatment for 30 minutes. The effect of PD98059 treatment on the regulation of 
COX-2 protein activity was examined by radioimmunoasay to measure the amount of 
PGE2 generated by COX-2. The amount o f PGE2  was used as an indication of COX-2
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protein activity. For the measurement o f COX-2 activity, 0.5 x 106 cells per well were 
plated in 24-well plates and grown for 18 hours to double the number of cells. After 18 
hours, RAW 264.7 cells were treated with LPS (1 pg/ml) plus PD98059 in the same 
concentrations previously used for the inhibition of ERK-1 and ERK-2 for 8 hours. 
After 8 hours, the culture media was removed and arachidonic acid (30 pM) as an 
exogenous substrate of COX-2 was added to cells for 10 minutes. The conditioned 
culture media was removed and analyzed by radioimmunoassay to measure the amount 
of prostaglandin E2 (PGE2) produced by COX-2. Second, to examine whether 
inhibition o f LPS-induced activation of P38 MAP kinase is also involved in the 
regulation of COX-2 expression, RAW 264.7 cells were pretreated with SB203580 at 
different concentrations (0,0.05,0.25, 1.25, 6.25,12.5, and 37.5 pM) for 1 hour in the 
absence of LPS. After pretreatment, RAW 264.7 cells were washed with DMEM 
containing 1% antibiotics (penicillin/streptomycin) three times. After washing, RAW
264.7 cells were treated with LPS (I pg/ml) plus SB203580 in the same concentrations 
used in pretreatment for 30 minutes. For the inhibition o f COX-2 expression, RAW
264.7 cells were treated with LPS (1 pg/ml) plus SB203580 in the same concentrations 
previously used for the inhibition of P38 MAP kinase for 8 hours without pretreatment.
For the time course of LPS-induced NF-kB activation, RAW 264.7 cells were 
treated without or with LPS (1 pg/ml) for different time periods (0, 1, 5, 10,20,30,60, 
and 120 minutes). Since it has been shown that NF-kB activation following the 
treatment o f agonists correlates with rapid proteolytic degradation of IkB-a protein 
induced by agonists, LPS-induced degradation of IkB-a protein was used as an 
indication o f NF-kB activation. To examine whether inhibition of LPS-induced
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activation of NF-kB is involved in the regulation of COX-2 expression, an NF-kB 
inhibitor, Z-LLF-CHO, was used and inhibition of IkB-a degradation was examined as 
an indication of NF-kB activity. For the inhibition of IkB-a degradation, RAW 264.7 
cells were pretreated with Z-LLF-CHO at different concentrations (0, 1, 5, and 10 pM) 
for 1 hour in the absence of LPS. After pretreatment, RAW 264.7 cells were washed 
with DMEM containing 1% antibiotics (penicillin/streptomycin) three times. Following 
a wash, RAW 264.7 cells were treated with LPS (1 pg/ml) plus Z-LLF-CHO in the 
same concentrations used in pretreatment for 30 minutes. For the inhibition of COX-2 
expression, RAW 264.7 cells were treated with LPS (1 pg/ml) plus Z-LLF-CHO in the 
same concentrations previously used for the inhibition of IkB-a degradation for 8 hours 
without pretreatment.
To examine whether both inhibition of LPS-induced activation of MAPKs and 
NF-kB is involved in the regulation of COX-2 expression, the inhibitors of protein 
tyrosine kinases (PTKs), such as Radicicol and Herbimycin A, were applied. For the 
inhibition of MAPKs, RAW 264.7 cells were pretreated with Radicicol in different 
concentrations (0,0.001,0.01,0.1, and 1 pg/ml) or Herbimycin A at the concentration 
of 0.5 pg/ml for 3 hours in the absence of LPS. After pretreatment, RAW 264.7 cells 
were washed with DMEM containing 1% antibiotics (penicillin/streptomycin) three 
times. Following a wash, RAW 264.7 cells were treated with LPS (1 pg/ml) plus 
Radicicol or Herbimycin A for 30 minutes. For the inhibition o f COX-2 expression, 
RAW 264.7 cells were treated with LPS (1 pg/ml) plus Radicicol or Herbimycin A for 8 
hours without pretreatment.
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2.3. Sample Preparation
For anti-phosphotyrosine immunoblotting analysis (see section 2.4.), RAW
264.7 cells treated with known activators and/or inhibitors of MAPKs for 30 minutes 
were washed with ice-cold phosphate buffered saline (PBS) containing 1 mM sodium 
vanadate (Na3V0 4 ), which is an inhibitor of protein tyrosine phosphatases (PTPs). 
Following a wash, cells were lysed in buffer [50 mM Tris-HCl (pH 7.4), 10 mM EDTA, 
1% (v/v) Tween-20,1% (v/v) Triton X-100,10 pM leupeptin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium vanadate (Na3V0 4 )] and set on 
ice for 20 minutes. Cell lysates were collected on ice and centrifuged at 14,000 rpm 
(10,000 x g) for 20 minutes at 4° C. After centrifugation, the supernatant was 
transferred to a 1.5-ml tube and the protein concentrations were measured by the 
Bradford method. Solubilized proteins were used for anti-phosphotyrosine 
immunoblotting analysis. The same cell lysates used for anti-phosphotyrosine 
immunoblotting analysis were also used for western blotting analysis (see section 2.5.) 
for the detection of JNK-1, IkB-a or immunoprecipitation (see section 2.6.) for the 
detection of ERK-2, P38 MAP kinase.
For ribonuclease protection assay (see section 2.11.), RAW 264.7 cells were 
treated with known activators of MAPKs for 4 hours and washed with ice-cold PBS 
without sodium vanadate. After washing, cells were lysed in TRIZOL reagent 
(Quiagen) (3 ml/60-mm size plate) by passing the cell lysates several times through a 
pipette. The homogenized samples were incubated for 5 minutes at room temperature to 
permit the complete dissociation o f nucleoprotein complexes and then mixed with 
chloroform (0.2 ml/1 ml TRIZOL reagent). Following vigorous shaking, the samples
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were incubated at room temperature for 3 minutes and centrifuged 12,000 x g for 15 
minutes at 4° C. After centrifugation, only the aqueous phase containing RNA was 
transferred to a 1.5-ml tube and the RNA from the aqueous phase was precipitated by 
mixing with isopropanol (0.5 ml/1 ml TRIZOL reagent). Following incubation for 10 
minutes at room temperature, the samples were centrifuged at 12,000 x g for 15 minutes 
at 4° C. After removing the supernatant, the RNA pellet was washed with 75% ethanol 
(1 ml/1 ml TRIZOL reagent) and centrifuged at 7,500 x g for 5 minutes at 4° C. The 
washed RNA pellet was briefly dried for 5-10 minutes at RT. The dried RNA pellet 
was dissolved in TE buffer (Tris-Cl, EDTA, pH 8.0) and the concentration of RNA was 
measured at OD260/280-
For COX-2 and GAPDH western blotting analysis (see section 2.5.), RAW
264.7 cells were treated with activators and/or inhibitors for 8 hours and washed with 
ice-cold PBS in the absence of sodium vanadate. Following a wash, cells were 
harvested in lysis buffer [50 mM Tris-HCl (pH 7.4), 1 mM sodium- 
diethyldithiocarbamic acid (Na-DDTC), 10 mM EDTA, 1% (v/v) Tween-20,1% (v/v) 
Triton X-100, 10 pMleupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF)] for 20 
minutes on ice. Cell lysates were sonicated (35 strokes) on ice and centrifuged at
14,000 rpm (10,000 x g) for 30 minutes at 4° C. After centrifugation, the supernatant 
was saved and the protein concentrations were measured by the Bradford method. 
Solubilized proteins were used for COX-2 and GAPDH western blotting analysis.
2.4. Anti-Phosphotyrosine Immunoblot Analysis
The purpose of anti-phosphotyrosine immunoblotting analysis is to examine 
proteins that are tyrosine phosphorylated in RAW 264.7 cells following stimulation.
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For this assay, mouse monoclonal anti-phosphotyrosine antibody (also designated as 
4G10) was used because it specifically recognizes proteins containing phosphorylated 
tyrosine residues. Solubilized proteins (80 pg) prepared previously (see section 2.3.) 
were separated on a 12% sodium dodecyl sulfate (SDS) polyacrylamide gel. Following 
electrophoresis, separated proteins on gel were transferred to a polyvinylidene difluoride 
(PVDF) transfer membrane (Millipore) in cold transfer buffer (10 mM Na2CC>3 , 3 mM 
NaHC0 3 , 20 % v/v methanol, pH 9.9). The membrane was then blocked in Tris- 
buffered saline-0.1% (v/v) Tween 20 (TBST) containing 3% (w/v) bovine serum 
albumin (BSA, Sigma) for 2 hours at room temperature or overnight at 4° C with slow 
shaking. After blocking, the membrane was washed in TBST at room temperature and 
then incubated in TBST containing mouse monoclonal anti-phosphotyrosine antibody 
(4G10) (1:2,000 dilution) for 1 hour at room temperature or overnight at 4° C with slow 
shaking. The membrane was washed in TBST and then incubated in TBST containing 
goat anti-mouse IgG coupled to horseradish peroxidase (1:5,000 dilution) at room 
temperature for 1 hour. Finally, the membrane was washed in TBST and then treated 
with enzyme chemiluminescence (ECL) western blotting detection reagent (Amersham) 
for 1 minute at room temperature. The membrane was briefly dried and exposed on an 
ECL western detection film (Amersham) at room temperature in the dark room. The 
exposed film was developed. After anti-phosphotyrosine immunoblotting analysis, the 
membrane was stripped in stripping buffer and reprobed with appropriate antibodies to 
locate the tyrosine phosphorylated proteins. Briefly, the same membrane used for anti- 
phosphotyrosine immunoblotting was stripped in stripping buffer [50 mM Tris-HCl,
100 mM p-mercaptoethanol, 2% (w/v) SDS, pH 6.5] at 50° C for 1 hour with slow
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shaking in order to remove antibodies attached on the membrane. Following a wash, 
the stripped membrane was reprobed with appropriate antibodies such as anti-ERK-1, 
anti-ERK-2, anti-P38, anti-JNK-1, anti-IkB-a, or anti-Lyn antibodies.
2.5. Western Blot Analysis
The purpose of western blotting analysis is to quantitatively compare the total 
amount of protein following treatment. The basic procedure of this analysis was similar 
to that of anti-phosphotyrosine immunoblotting analysis (see section 2.4), described 
previously. Briefly, 80 pg of solubilized proteins were separated on 8% SDS- 
polyacrylamide gel for JNK-1, COX-2, and GAPDH western blotting analysis or 12% 
SDS-polyacrylamide gel for IkB-a western blotting analysis. Following electrophoresis, 
separated proteins on the gel were transferred to a PVDF transfer membrane with the 
same conditions described previously (see section 2.4.). However, the membrane was 
blocked in Phosphate buffered-saline (PBS)-0.l% (v/v) Tween 20 (PBST) containing 
5% (w/v) non-fat dried milk (Carnation, San Francisco, CA) with slow shaking 
overnight at 4° C. After blocking, the membrane was washed in PBST and then 
incubated in PBST containing appropriate antibodies for 1 hour at room temperature. 
These antibodies included rabbit polyclonal anti-P38 (1:10,000 dilution), anti-ERK-2 
(1:10,000 dilution), anti-Lyn (1:2,000 dilution), anti-c-Src (1:1,000 dilution), anti-Flag 
(1:2,000), anti-JNK-1 (1:2,000 dilution), anti-IkB-a (1:1,000 dilution), anti-COX-2 
(1:10,000 dilution), or anti-GAPDH (1:10,000 dilution) antibodies. Following 
incubation with primary antibodies, the membrane was washed in PBST and then 
incubated in PBST containing sheep anti-rabbit IgG coupled to horseradish peroxidase 
(1:5,000 dilution) as a secondary antibody for 1 hour at room temperature with slow
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shaking. Finally, the membrane was washed in PBST and treated with ECL western 
blot detection reagent for 1 minute at room temperature. The membrane was exposed to 
an ECL western film and the exposed film was developed.
2.6. Immunoprecipitation
The purpose of immunoprecipitation is to qualitatively identify and purify each 
protein of interest by immunoprecipitating it with its specific antibody. The proteins 
immunoprecipitated in this study include ERK-2, P38, JNK-1, Lyn, Flag-tagged Lyn, 
and COX-2 proteins. To identify and purify ERK-2, P38, JNK-1, or COX-2 proteins 
affected by LPS or other agents, cell lysates were prepared from RAW 264.7 cells 
unstimulated and stimulated with LPS or other agents and the ceil lysates were 
immunoprecipitated with their specific antibodies. Following immunoprecipitation, the 
immunoprecipitates were analyzed by western blot analysis using anti-ERK-2, anti-P38, 
anti-JNK-1, or anti-COX-2 antibodies. To determine tyrosine-phosphorylated ERK-2 or 
P38, cell lysates from LPS-stimulated RAW 264.7 cells were first immunoprecipitated 
with anti-ERK2 antibody or anti-P38 antibody and the immunoprecipitates containing 
ERK-2 or P38 were analyzed by anti-phosphotyrosine immunoblotting with an anti- 
phosphotyrosine antibody (4G10). The best conditions of the ratio between the amount 
of samples and the amount o f antibody for immunoprecipitation were different for each 
protein. For example, about 100 pg of solubilized proteins and 2 pg o f anti-ERK-2 
antibody were needed to show better immunoprecipitation results for ERK-2 analysis. 
For Lyn analysis, about 500 pg of solubilized proteins and 5 pg of anti-Lyn antibody 
were needed for immunoprecipitation. For JNK-1, about 200 pg of solubilized proteins 
and 0.2 pg of anti-JNK-1 antibody were used for IMP o f JNK-1. Following
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immunoprecipitation, the immunocomplexes containing each antigen and antibody were 
further incubated in PBS containing protein A-sepharose beads for 3 hours at 4° C and 
then centrifuged at 14,000 rpm (10,000 x g) at 4° C for 5 minutes. The supernatant 
(SUP) was saved and concentrated with Centricon-10 (Amicon) by centrifugation at
6,000 rpm at 4° C to be about 80 pi o f a final volume. The pellets containing a complex 
of antigen-antibody-protein A-sepharose beads were washed in ice-cold PBS. Each 
washing step was followed by centrifugation at 14,000 rpm (10,000 x g) at 4° C for 3 
minutes. After the final centrifugation, any residual solution in the upper phase was 
completely removed by repeated pipetting. The pellets were then resuspended in 80 pi 
of 2 x Laemmli buffer and boiled at 100° C for 5 minutes. The boiled pellets were 
centrifuged at 14,000 rpm (10,000 x g) at 4°C for 5 minutes. After centrifugation, the 
upper phase was saved. Both fraction of the immunoprecipitation were loaded on a 
10% SDS-polyacrylamide gel for western blot analysis or a 12% SDS-polyacrylamide 
gel for anti-phosphotyrosine immunoblotting analysis.
2.7. Radioimmunoassay
The purpose of radioimmunoassay is to measure the amount of prostaglandin E2 
(PGE2) produced by COX-2 following treatment. The assay was performed according 
to the method previously described (Fu et al., 1990) with modification. RAW 264.7 
cells were incubated in DMEM containing 10% FBS with LPS or other agents for 8 
hours. The culture media was removed, and the cells were incubated in the fresh 
DMEM containing arachidonic acid (30 pM) as COX-2 substrate for 10 minutes. The 
conditioned culture media was removed and analyzed to measure the amount o f PGE2
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produced by COX-2. The amount of PGE2 was used as an indication of COX-2 protein 
activity.
2.8. In-Gel Kinase Assay for ERK-1, ERK-2, and JNK-1
To determine the kinase activity of MAPKs following stimulation, an in-gel 
protein kinase assay was performed using exogenous substrates with [y-32P] ATP. Two 
exogenous substrates were used in the assay: myelin basic protein (MBP) as an ERK-1 
& ERK-2 substrate and the activating transcription factor 2 (ATF2) as a JNK-1 substrate 
(Derijard et al., 1995). The assay was performed according to the method previously 
described (Kameshita, I., and Fujisawa, H., 1989; Gotoh et al., 1990; Campos- 
Gonzalez, R., and Glenney, Jr., J. R., 1992) with modification. The same samples from 
RAW 264.7 cells treated with LPS plus the inhibitors [PD98059 (the inhibitor of MEK- 
1 and MEK-2) or Radicicol and Herbimycin A (the inhibitors of protein tyrosine 
kinases)] for anti-phosphotyrosine immunoblotting analysis (see section 2.4) were used 
for this assay. For the measurement of ERK-1 and ERK-2 kinase activity, 100 pg of 
solubilized proteins were resolved on a 10% SDS-polyacrylamide gel containing 5 mg 
of MBP as an ERK-1 and ERK-2 substrate. For the measurement of JNK-1 kinase 
activity, the same procedures used for measuring ERK-1 and ERK-2 kinase activity 
were followed except the use of 5 mg of purified glutathione-S-transferase (GST)-ATF2 
(see section 2.8.1.) as a JNK-1 substrate instead of MBP. These substrates were added 
in the separation gel just prior to polymerization and evenly distributed in the separation 
gel. After electrophoresis, SDS in the gel was removed by washing the gel twice with 
each 200 ml o f SDS removal buffer [20% p-isopropanol in 50 mM Tris-HCl (pH 8.0)] 
for 1 hour at RT with gentle agitation, and once more with 250 ml of 50 mM Tris-HCl
48
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(pH 8.0) containing 5 mM P-mercaptoethanol (Buffer A). To denature proteins in the 
gel, the gel was treated with two changes of 200 ml of Buffer A containing 6  M 
guanidine-HCl at RT for 30 minutes. To renature proteins in the gel, the gel was treated 
with five changes o f250 ml o f Buffer A containing 0.04% Tween 40 (pH 8.0) at 4° C 
for 16 hours with gentle agitation. After renaturation, the gel was preincubated in 40 
mM HEPES-NaOH (pH 8.0) containing 2 mM dithiothreitol (DTT), 0.1 mM EGTA, 
and 5 mM MgCl2  at 25° C for 30 minutes. The kinase reaction was carried out by 
incubating the gel in 40 mM HEPES-NaOH (pH 8.0) containing 2 mM dithiothreitol 
(DTT), 0.1 mM EGTA, 5 mM MgCl2, 50 pM ATP, and 50 pCi of [y-32P] ATP 
(3,000Ci/mmol, 5 pCi/pl) at 25° C for 1 hour. After the kinase reaction, the gel was 
washed with 5% (w/v) trichloroacetic acid (TCA) solution containing 1% sodium 
pyrophosphate at RT until the radioactivity of the solution became negligible. The gel 
was then dried on Whatmann 3MM filter paper in gel dryer at 80° C for 1 hour. The 
dried gel was exposed to Kodak X-ray film. The kinase activity of ERK-1 & ERK-2 or 
JNK-1 was assessed by the extent of incorporated y-32P in MBP by ERK-1 & ERK-2 or 
ATF2 by JNK-1.
2.8.1. Purification of GST-ATF2 Fusion Protein
ATF2 is a known JNK-1 substrate (Fuchs et al., 1997). pGEX-3T/ATF2 
plasmid DNA encoding GST-ATF2 fusion proteins (provided by Dr. R. J. Davis) was 
transformed in E. coli DH-5a (GIBCO-BRL) by electroporation. To purify GST-ATF2 
fusion protein from transformed E.coli bacteria harboring the pGEX-3T/ATF2 plasmid 
DNA, glutathione sepharose 4B-column (Pharmacia Biotech.) was applied, and the 
column purification procedure was performed according to the manufacturer’s
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instruction. Briefly, following electroporation, a single colony of transformed E. coli 
DH-5a was inoculated in LB (Luria Bertani) media containing 100 pg/ml of ampicillin 
because of the presence of ampicillin-resistant genes in the pGEX-3T/ATF2 plasmid) 
and further grown with vigorous shaking (250 rpm) overnight at 37° C. The cell culture 
was then diluted to 1:10 in new LB media containing 100 pg/ml of ampicillin and 
allowed to grow at 37° C for 1-3 hours with vigorous shaking. Bacterial growth was 
induced with isopropyl-p-thio-galactopyranoside (IPTG) to a final concentration of 0.1 
mM as a growth inducer and continued to grow at 37° C for an additional 3 hours.
When the ODeoo value reached 1.5-2.0, the culture suspension was transferred to clean 
tubes and centrifuged at 8,000 rpm (7,700 x g) for 10 minutes at 4° C. The supernatant 
was removed and the bacteria pellets were resuspended in ice-cold PBS (150 mM NaCl, 
16 mM Na2HPC>4 , 4 mM NaEhPO^ pH 7.3) and then incubated on ice for 10 minutes. 
The resuspended pellets were sonicated at 35 strokes and then clarified by centrifugation 
at 8,000 rpm (7,700 x g) for 10 minutes at 4° C. The supernatant was transferred to a 
clean tube and Triton X-100 was added to the final concentration as 1% using 20% 
stock in PBS. The supernatant containing 1% Triton X-100 was incubated for 30 
minutes on ice and centrifuged at 10,000 rpm (12,000 x g) for 10 minutes at 4° C. The 
supernatant was then filtered with 0 . 2  jaM filter. The filtrate was collected for column 
purification using glutathione sepharose 4B-column. The column used according to the 
manufacturer’s instruction. The column was drained to remove the 20 % ethanol 
storage preservative and washed with 10 ml of PBS twice. The column was equilibrated 
with 20 ml o f PBS containing 1% Triton X-100. The filtrate was slowly loaded on the 
column and drained off completely. The column was then washed with PBS. The
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proteins bound on the column were eluted by adding elution buffer (5 mM glutathione 
in 50 mM Tris-HCl, pH 8.0) and each eluate (fraction) was collected in a final volume 
of 2 ml. The OD596 value of each eluate containing GST-ATF2 fusion proteins was 
measured and the amount of purified proteins was calculated. The existence of GST- 
ATF2 fusion proteins was determined on a 10 % gel by a Coomasie staining. The 
purified GST-ATF2 fusion proteins were used as a JNK-1 substrate for in-gel JNK-1 
kinase assays to measure the activity of JNK-1 (see section 2.8.).
2.9. Immune-Complex Kinase Assay for Lyn
To measure the kinase activity of Lyn, immunocomplex kinase assays were 
performed using acid-denatured enolase (see section 2.9.1.) as a general substrate of Lyn 
kinase with [y-P32] ATP. Cell lysates (500 pg of solubilized proteins) from wild type 
and mutant Flag-tagged lyn DNA-infected and puromycin selected NIH/3T3 cells (see 
section 2.13.) were immunoprecipitated with 5 pg of anti-Lyn antibody at 4° C for 3 
hours. The immunocomplexes were further incubated with protein A-sepharose beads 
(20% v/v) for 2 hours and then centrifuged at 14,000 rpm (10,000 x g) for 5 minutes at 
4° C. Following centrifugation, the supernatant was removed and the 
immunocomplexes were washed with RIPA buffer [50 mM Tris-Cl (pH 7.4), 150 mM 
NaCl, 1% (v/v) Nonidet P (NP)-40, 1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1 mM 
NasVO,*, leupeptin (10 pg/ml), and aprotinin (10 pg/ml)]. The immunocomplexes were 
washed with kinase reaction buffer [100 mM HEPES-NaOH (pH 7.2), 10 mM MnCL]. 
After removing the residual washing solution, the immunocomplexes were preincubated 
in the same kinase reaction buffer for 1 0  minutes and then incubated in the same kinase 
reaction buffer containing 9 pg o f acid-denatured enolase and 10 pCi [y-P32] ATP
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(3,000 Ci/mmol, 5 jj.Ci/fj.1). The kinase reaction was stopped by the addition of 
Laemmeli buffer and boiled at 100° C to dissociate the immunocomplexes, centrifuged 
at 14,000 rpm (10,000 x g) for 5 minutes at 4° C and the supernatant was loaded on 10% 
SDS-polyacrylamide gel. Following electrophoresis, the gel was washed until the 
radioactivity of the solution became negligible. The washed gel was dried in a gel drier 
at 80° C for 1 hour. The dried gel was exposed to Kodak X-ray film at RT. The extent 
of incorporated y-P in enolase used as an assessment of Lyn kinase activity.
2.9.1. Preparation of Acid-Denatured Enolase
Five hundred micrograms of rabbit muscle enolase (3.2 pg/pl, Sigma) was 
centrifuged at 14,000 rpm (10,000 x g) at 4° C for 5 minutes. The pellet was resuspended 
in resuspension buffer [50 mM HEPES-NaOH (pH 7.0), 1 mM DTT, 1 mM MgCh] and 
incubated for 1 hour on ice. The resuspended pellet was denatured in 50 mM NaOAc- 
AcOH (pH 3.3) by incubating at 30° C for 5 minutes. The immunocomplex kinase assay 
for Lyn (see section 2.9.) used about 9 pg of acid-denatured enolase per reaction.
2.10. In Vitro Transcription
Using in vitro transcription method, radiolabeled RNA probes (antisense) of 
COX-2 and GAPDH were prepared for ribonuclease protection assay (see section 2.11.) 
for the detection of COX-2 and GAPDH mRNA (sense) from unstimulated and 
stimulated RAW 264.7 cells. In vitro transcription was performed using MAXIscript™ 
kit (Ambion) and followed protocols recommended by the manufacturer. To linearize the 
circular form of pOSML plasmid DNA containing fiill-lengths of mouse COX-2 or 
GAPDH cDNA, the plasmids were incubated in reaction mixture [pOSML plasmids 
containing COX-2 or GAPDH cDNA, 10 x reaction buffer (#3, GIBCO-BRL), and Not I
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at 37° C for 4 hours. To determine whether the linearization of circular plasmids by Not I 
was complete, a portion of linearized plasmids was run on 1% agarose gel. After 
determining complete linearization, the reaction mixture was heated to inactivate Not I at 
65° C for 15 minutes. To purify the linearized plasmids, the reaction mixture was placed 
in phenolxhloroform (1:1) mixtures and centrifuged at 8,000 x g at 4° C for 5 minutes. 
The aqueous layer containing DNA was transferred to a 1.5 ml tube and an equal volume 
of chloroform was added, followed centrifugation at 8,000 x g 4° C for 1 minute. The 
aqueous layer was transferred to another 1.5 ml tube and both 1/10 volume of 3 M NaOAc 
and 2 volume of cold absolute ethanol were added and then incubated at - 20° C for 15 
minutes, followed centrifugation at 12,000 x g for 15 minutes at 4° C. The supernatant 
was removed and the pellet was washed with cold 75% ethanol. After centrifugation at 
12,000 x g at 4° C for 5 minutes, the supernatant was removed and the DNA pellet was 
dried. The dried DNA pellet was then resuspended in TE buffer (10 mM Tris-Cl, 1 mM 
EDTA, pH 7.6). The final concentration of linearized and purified plasmids was 
measured at OD26o- Complementary RNA (cRNA) probe was synthesized from linearized 
plasmids by using a MAXIscript™ kit. To generate radiolabeled RNA probes, the 
following reaction mixture was assembled in order: linearized DNA template (COX-2 or 
GAPDH, 1 pg), 200 mM DTT (1 pi), 10 mM ATP (1 pi), 10 mM CTP (1 pi), 10 mM 
GTP (1 pi), 10 x  Transcription buffer (2 pi), RNase inhibitor (1 pi), 0.1 M UTP (0.05 pi), 
[a-32P] UTP (5 pi, 400-800 Ci/mmol), T7 RNA polymerase (10 units/pl), RNase free 
water. The reaction mixture was incubated at RT for 1 hour. To digest linearized DNA 
templates, DNase I was added to the reaction mixture and incubated at 37° C for 15 
minutes, followed by inactivation of DNase I by the addition of 0.2 M EDTA. The
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reaction mixture was loaded on a  5% acrylamide-8 M urea gel to separate radiolabeled 
RNA probe of COX-2 or GAPDH. After electrophoresis, the gel was exposed to a Kodak 
film and was developed. The film was overlaid on the gel to mark the spots containing 
radiolabeled RNA probes and the gel spots marked were excised. The radiolabeled RNA 
probes were eluted from the excised gels by placing in the elution buffer at 37° C 
overnight. A portion of each radiolabeled probe of COX-2 or GAPDH from the eluate 
was added to scintillation cocktail (Ecolite™, ICN) to measure the radioactivity o f COX-2 
or GAPDH probes. The fractions having higher radioactivity were pooled and the 
radioactivity of the pooled probes was measured.
2.11. Ribonuclease Protection Assay
The purpose of the ribonuclease protection assay (RPA) is to detect the level of 
mRNA (sense) of COX-2 or GAPDH extracted from RAW 264.7 cells unstimulated and 
stimulated with LPS or other agents for 4 hours. Using radiolabeled RNA probes 
(antisense) of COX-2 or GAPDH prepared by in vitro transcription method (see section
2.10.) described previously, ribonuclease protection assay kit (RPA H™, Ambion) was 
used and the assay was basically performed according to the protocols recommended by 
the manufacturer. Total cellular RNA from unstimulated and stimulated RAW 264.7 
cells was extracted using TRIZOL reagent (GIBCO-BRL) and the concentration of total 
cellular RNA was measured at OD260- Two micrograms of total cellular RNA were 
hybridized with both radiolabeled GAPDH (4 x 104 cpm) and COX-2 (8 x 104 cpm) 
probes in a tube. To co-precipitate both sample mRNA and probe cRNA of COX-2 or 
GAPDH, NH4OAC (0.5 M) and absolute ethanol (2.5 volumes) were added to the tube 
and incubated in -  20° C for 15 minutes and centrifuged at 14,000 rpm (10,000 x g) for
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15 minutes at 4° C. The ethanol supernatant was removed and the RNA pellets were 
dissolved in hybridization buffer and immediately incubated at 90° C for 4 minutes to 
denature or solubilize RNAs. The following hybridization reaction was carried out in a 
45° C water bath for 18 hours to allow complete hybridization of radiolabeled RNA 
(antisense) probe and sample mRNA (sense) because of complementarity. After 
hybridization, diluted RNase mixture was added to the tube and incubated at 37° C for 
30 minutes to digest unprotected single-stranded or unhybridized RNAs. The RNase 
inactivation and precipitation mixture was then added to the tube and further incubated 
at -  20° C for 15 minutes. The tube was centrifuged at 14,000 rpm (10,000 x g) at 4° C 
for 15 minutes. The supernatant was removed and the RNA pellets were resuspended in 
loading buffer and heated at 90° C for 4 minutes to solubilize and denature RNA. The 
heated RNA samples were run on 6% acrylamide gel containing 8 M urea. After 
electrophoresis, the gel was covered with a piece of plastic wrap and exposed on an X- 
ray film in the dark room. The ratio of radioactivity between the COX-2 and GAPDH 
bands on the gel was determined by scanning the gel with Phosphorlmager (Molecular 
Dynamics, California).
2.12. DNA Sequencing
We used DNA sequencing to verify whether the Flag-epitope sequence was 
correct in wild type and mutant Flag-tagged lyn cDNAs of the pBPSTRl retroviral 
vector and the mutation in mutant lyn cDNA [Y508F, the tyrosine (Y) residue on 508 
position in the C-terminal regulatory domain of Lyn is replaced with phenylalanine (F)] 
is also correct. The assay was basically performed according to a Sequenase™ Quick- 
Denature™ Plasmid Sequencing Kit (United States Biochemical, USB) and the
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protocols recommended by the manufacturer. For alkali denaturation of double strand 
DNA, 2 pg o f lyn cDNAs (wild type or mutant) were incubated in 3 pi of alkali solution 
(2 M NaOH, 2 mM EDTA) at RT for 5 minutes. To neutralize the reaction, 3 pi of 2 M 
NH4CH3CO2  (pH 4.6) was added to the reaction tube and mixed by vortexing. Cold 
absolute ethanol (- 20° C) was added and the tube was placed at - 20° C for 10 minutes. 
The tube was centrifuged at 14,000 rpm (10,000 x g) at 4°C for 10 minutes. The 
supernatant was removed and the DNA pellet was shortly dried at room temperature. 
The dried DNA pellet was then resuspended in TE buffer (10 mM Tris-Cl, 1 mM 
EDTA, pH 8.0). For annealing, the resuspended DNA (5 pi) was mixed with ddHjO (2 
pi), annealing reaction buffer (2 pi), and primer (1 pi). The annealing reaction was 
carried out at 65° C for 2 minutes and then cooled slowly to 35° C by removing the 
heating iron template to room temperature. For radiolabeling, the annealed DNA 
mixture (10 pi) was incubated in a mixture o f 0.1 M DTT (1 pi), diluted labeling 
reaction buffer (2 pi), [35S] deoxyadenosine triphosphate (dATP) (0.7 pi), and diluted 
sequenase polymerase (2 pi) at room temperature for 3 minutes. For radiolabeling 
termination, 3.5 pi of the radiolabeled reaction mixture was placed in 4 different tubes 
containing 2.5 pi of each termination mixture (A, G, C, and T) and the tubes were 
incubated at 37° C for 5 minutes. After 5 minutes, each tube was mixed with 4 pi of 
reaction stop solution and then heated at 75° C for 5 minutes. For DNA separation, the 
heated DNA samples (3.2 pl/lane) were loaded onto a DNA sequencing gel and run 
under 2,500 volts at 50-60° C for about 1.5-2.0 hours. After running, the gel was 
overlaid by Whatmann 3MM paper in appropriate size and covered with a plastic wrap.
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The gel was then dried at 80° C for 1 hour in gel dryer. The dried gel was exposed on a 
DNA sequencing film (Kodak) and developed.
2.13. Transfection, Infection, and Antibiotic Selection
The purpose of transfection, infection, and antibiotic selection is to determine 
whether lyn cDNAs is correctly transfected and infected to cells, and to select only cells 
expressing the products of lyn cDNAs under puromycin (antibiotic) treatment because 
o f puromycin-resistance genes in the pBPSTRl vector. The overall purpose is to 
examine whether overexpression of mutant Lyn can induce the expression of COX-2 in 
cells. For the transfection of lyn cDNAs to cells, SuperFect reagent (Quiagen) was 
applied. This reagent, having positive charges, can interact with the negative charges in 
DNA and form DNA-SuperFect reagent complexes that make them permeable to the 
cell membrane.
2.13.1. Transfection of lyn cDNAs to Phoenix Cells
Phoenix (d>NX) cells (a packaging cell line) were maintained in complete 
DMEM containing 10% (v/v) heat-inactivated fetal bovine serum and 1% (v/v) 
antibiotics (penicillin/streptomycin) at 37° C in 5% CCh/air mixtures. For transfection 
experiment, about 0.5 ~ 1.0 x 106 ONX cells were plated into a 60-mm dish in 4 ml o f 
complete DMEM containing 2 pg/ml of tetracycline the night before transfection. 
Tetracycline was used to control the expression of lyn cDNA because the transcription 
of any insert DNA in the pBPSTRl vector can be controllable by the presence or 
absence o f tetracycline (Pear et al., 1993; Paulus et al., 1996). To prepare 
DNA/SuperFect reagent complexes, 5 pg o f lyn cDNAs was diluted with DMEM 
without containing serum and antibiotics to be a final volume of 150 pi in a 1.5-ml tube.
57
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
SuperFect reagent (20 pi) was added to the tube containing lyn cDNAs and gently 
mixed. The DNA/SuperFect reagent complexes were incubated for 10 minutes at room 
temperature. At the same time, the culture media was removed from ONX cells and the 
cells were washed with 4 ml of DMEM containing 1% penicillin/streptomycin twice. 
After 10 minutes, 1 ml of DMEM supplemented with 10 % heat-inactivated FBS and 
1% penicillin/streptomycin was added to the tube containing DNA/SuperFect reagent 
complexes and gently mixed. The DNA/SuperFect reagent complexes were 
immediately transferred to the ONX cells. After 3 hours post-transfection, the culture 
media was removed and then washed with DMEM supplemented with 10 % heat- 
inactivated FBS and 1% penicillin/streptomycin. Transfected ONX cells were then 
grown in 4 ml of DMEM supplemented with 10 % heat-inactivated FBS, 1% 
penicillin/streptomycin, and 2 pg/ml of tetracycline for 21 hours. After 21 hours post­
transfection, the culture media was removed and replaced with 2 ml of DMEM 
supplemented with 10 % heat-inactivated FBS, 1% penicillin/streptomycin, and 2 pg/ml 
of tetracycline for additional 24 hours. Meanwhile, 0.2 x  106 NIH/3T3 cells were plated 
in 4 ml of DMEM supplemented with 10 % heat-inactivated FBS, 1% 
penicillin/streptomycin, and 2 pg/ml of tetracycline the night prior to infection.
2.13.2. Infection of NIH/3T3 Cells with Viral Particles Produced by Transfected 
Phoenix Cells
After 48 hours post-transfection, the culture media containing infectious viral 
particles produced by transfected ONX cells was transferred to a 15 ml tube and 
centrifuged at 1,500 rpm for 5 minutes at room temperature. Following centrifugation, 
the supernatant containing infectious viral particles was used to infect NIH/3T3 cells.
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For infection, the culture media from NIH/3T3 cells plated the night prior to infection 
was removed and replaced with 2 ml of DMEM supplemented with 10 % heat- 
inactivated FBS, 1% penicillin/streptomycin, 8 pg/ml of polybrene (a polycationic 
substance, Sigma), and 2 pg/ml of tetracycline. Polybrene was used to increase the 
efficiency of viral infection. The supernatant containing infectious viral particles was 
added to NIH/3T3 cells and further incubated for 24 hours. After 24 hours post­
infection, the culture media was removed and replaced with 4 ml of DMEM 
supplemented with 10 % heat-inactivated FBS, 1% penicillin/streptomycin, and 2 pg/ml 
of tetracycline.
To determine whether wild or mutant type o f Flag-tagged Lyn proteins were 
successfully expressed in transfected ONX cells, the ONX cells were grown in DMEM 
supplemented with 10 % heat-inactivated FBS and 1% penicillin/streptomycin for 24 
hours, washed with ice-cold PBS twice and lysed in RIPA buffer [50 mM Tris-Cl (pH 
7.4), 150 mM NaCl, 1% (v/v) NP-40,1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1 mM 
Na3VC>4 , leupeptin (10 pg/ml), and aprotinin (10 pg/ml)] for 20 minutes on ice. Cell 
lysates were used for western blotting analysis (see section 2.5.) or immunoprecipitation 
(see section 2.6.) for Lyn or Flag detection using anti-Lyn antibody or anti-Flag 
antibody.
2.13.3. Antibiotic (Puromycin) Selection for Stable Clones
After 24 hours post-infection, infected NIH/3T3 cells were grown in DMEM 
supplemented with 10 % heat-inactivated FBS and 1 % penicillin/streptomycin in the 
presence of 2 pg/ml o f puromycin for several weeks. The pooled colonies and each 
colony that survived in the presence of puromycin during the selection periods were
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selected and grown for further studies. To determine the expression of wild or mutant 
type of Flag-tagged Lyn proteins, about 5 ~  10 x 106 NIH/3T3 cells (pooled colonies 
and each colony) were grown in 4 ml of DMEM supplemented with 10 % heat- 
inactivated FBS and 1 % penicillin/streptomycin for 24 hours. Cells were washed with 
DMEM containing 1 % penicillin/streptomycin twice and then lysed in RIPA buffer [50 
mM Tris-Cl (pH 7.4), 150 mMNaCl, 1% (v/v) NP-40,1 mM EGTA, 1 mM EDTA, 1 
mM PMSF, 1 mM Na3VC>4 , leupeptin (10 pg/ml), and aprotinin (10 pg/ml)] for 20 
minutes on ice. To examine the expression of Flag-tagged Lyn and COX-2, cell lysates 
were used for western blot analysis (see section 2.5.) or immunoprecipitation (see 
section 2.6.) using specific anti-Lyn, anti-Flag, or anti-COX-2 antibodies. Using these 
same samples, the activity of overexpressed wild type and mutant Lyn kinase in infected 
and selected NIH/3T3 cells was measured by an immunocomplex kinase assay (see 
section 2.9.) using an acid-denatured enolase and [y-P32] ATP as substrates. The 
enzymatic activity of COX-2 protein in infected and selected NIH/3T3 cells was 
measured by radioimmunoassay (see section 2.7.).
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CHAPTER 3 
RESULTS
3.1. Examination of the Involvement of LPS-induced Activation of MAPKs and 
NF-kB on the Expression of COX-2 in LPS-stimulated RAW 264.7 Cells
3.1.1. LPS-induced Activation of MAPKs alone appears to be insufficient to 
induce COX-2 Expression in LPS-stimulated RAW 264.7 Cells. The Activation of 
NF-kB induced by LPS appears to be necessary for COX-2 Expression.
Using known activators of MAPKs, such as PMA, sorbitol, H2 O2 , or 
combinations of these agents, we examined whether MAPK activation alone is 
sufficient to induce the expression o f COX-2 in RAW 264.7 cells.
In addition to LPS (1 pg/ml), RAW 264.7 cells were treated with PMA (100 
nM), sorbitol (0.4 M), H2O2 (1 mM) or combinations of these agents [PMA (100 nM) 
plus sorbitol (0.4 M) and PMA (100 nM) plus H2O2  (1 mM)] for 30 minutes. 
Solubilized samples were used for anti-phosphotyrosine immunoblotting analysis (see 
section 2.4.) and western blotting analysis (see section 2.5.). RAW 264.7 cells were 
also treated with the same agents used above for 4 hours, and total cellular RNA was 
isolated and used for RPA (see section 2.11.) to measure the level o f COX-2 mRNA 
expression. Cells were also treated with the same agents used above for 8 hours to 
perform RIA (see section 2.7.) to measure the enzyme activity of COX-2 protein.
Figure 7A shows that LPS treatment (1 pg/ml, lane 2) resulted in tyrosine 
phosphorylation of ERK-1, ERK-2, and P38 MAP kinase as measured by anti- 
phosphotyrosine immunoblotting analysis using anti-phosphotyrosine antibody (4G10), 
which can recognize proteins containing phosphorylated tyrosine residues. PMA 
treatment (100 nM, lane 3) caused strong tyrosine phosphorylation o f ERK-1 and ERK-
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Figure 7. Effects of LPS, PMA, sorbitol, H2O2, or combinations of these agents on 
the tyrosine phosphorylation of MAPKs, the expression of COX-2, and the 
degradation of IkB-a in RAW 264.7 cells.
Lane 1, vehicle; lane 2, LPS (1 pg/ml); lane 3, PMA (100 nM); lane 4, sorbitol (0.4 M); 
lane 5, PMA (100 nM) + sorbitol (0.4 M); lane 6, H20 2 (1 mM); lane 7, PMA (100 nM) 
+ H20 2 (I mM).
(A) Anti-phosphotyrosine immunoblot analysis (panel A). RAW264.7 cells were 
treated with the indicated agents for 30 minutes, and solubilized proteins were detected 
by an anti-phosphotyrosine antibody (4G10). ERK-1-P, phosphorylated ERK-1; P38-P, 
phosphorylated P38; ERK-2-P, phosphorylated ERK-2.
(B) JNK-1 western blot analysis (panel B). RAW 264.7 cells were treated with the 
indicated agent for 30 minutes, and solubilized proteins were detected by an anti-JNK-1 
antibody. JNK-1, nonphosphorylated JNK-1; JNK-1-P, phosphorylated JNK-1.
(C) Ribonuclease protection assay (RPA) (panel C). RAW264.7 cells were treated with 
the indicated agents for 4 hours. Total cellular RNA was extracted by TRIZOL 
reagents, and 2 pg of total RNA were analyzed by RPA. The expression level o f mRNA 
used as an internal control mRNA was compared with that of COX-2 mRNA induced 
by LPS.
(D) Radioimmunoassay (RLA) (panel D). RAW 264.7 cells were treated with the 
indicated agent for 8 hours, and then arachidonic acid (30 pM) as an exogenous 
substrate of COX-2 was added to the cells for 10 minutes. The conditioned culture 
media was removed and analyzed by RIA to measure the amounts of PGE2 produced by 
COX-2. The amounts o f PGE2 measured by RIA were used as an assessment o f COX-2 
activity.
(E) IkB-a western blot analysis (panel E). RAW 264.7 cells were treated with the 
indicated agent for 30 minutes, and solubilized proteins were detected by an anti-IkB-a 
antibody.
Panel A, B, and D are derived from Hwang, 1997.
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2. PMA treatment,however, did not cause tyrosine phosphorylation of P38 MAP 
kinase. Sorbitol treatment (0.4 M, lane 4) induced strong tyrosine phosphorylation of 
P38 MAP kinase and weak tyrosine phosphorylation of ERK-2. Sorbitol did not cause 
tyrosine phosphorylation of ERK-1. H20 2 treatment (1 mM, lane 6) resulted in strong 
tyrosine phosphorylation of ERK-1, ERK-2, and P38 MAP kinase. The treatments of 
combinations of these agents, such as PMA plus sorbitol (lane 5) or PMA plus H20 2 
(lane 7), caused strong tyrosine phosphorylation of ERK-1, ERK-2, and P38 MAP 
kinase. There was no tyrosine phosphorylation of ERK-1, ERK-2, and P38 MAP kinase 
in the control (no treatment, lane 1). These results show that these agents, including 
LPS, are apparent activators of ERK-1, ERK-2, or P38 MAP kinase in RAW 264.7 
cells.
The tyrosine phosphorylation o f JNK-1 following treatment of these agents was 
not detected by anti-phosphotyrosine antibody (4G10) in Figure 7A. To detect any 
change of JNK-1 induced by these agonists, including LPS, JNK-i western blotting 
analysis was performed using anti-JNK-1 antibody. The result of JNK-1 western blot 
analysis (Figure 7B) indicated that the treatments o f LPS (lane 2), sorbitol (lane 4),
H20 2 (lane 6), PMA plus sorbitol (lane 5), or PMA plus H20 2 (lane 7) resulted in an 
apparent electrophoretic mobility shift of JNK-1 in RAW 264.7 cells. However, PMA 
treatment (lane 3) alone did not cause the electrophoretic mobility shift o f JNK-1, 
similar to the control (no treatment, lane 1). These results show that LPS, sorbitol, and 
H20 2 are strong activators o f JNK-1, but PMA is not an activator of JNK-1 in RAW
264.7 cells. The results o f RPA are shown in Figure 7C. Only LPS treatment (lane 2) 
resulted in high induction of COX-2 mRNA expression in RAW 264.7 cells. The
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treatments of PMA (lane 3), sorbitol (lane 4), H2O2 (lane 6), or combinations of these 
agents, such as PMA plus sorbitol (lane 5) or PMA plus H2O2 (lane 7), failed to induce 
the induction of COX-2 mRNA expression in RAW 264.7 cells. The level of GAPDH 
mRNA expression, which was used as an internal control mRNA was constant in most 
lanes as shown in Figure 7C, except in lane 4 (sorbitol). The reason for this lower level 
o f GAPDH mRNA could be due to the loss of total cellular RNA or mRNA during 
sample preparation or RPA procedures. The constant levels of GAPDH mRNA and 
protein were observed in other RPA experiments and western blotting analyses using 
the same treatment agent (data not shown).
The results of RIA are shown in Figure 7D. Only LPS treatment (lane 2) 
resulted in high activity of COX-2 protein as assessed by the amounts of PGE2 
generated by LPS-induced COX-2 protein. LPS treatment caused about a 4.5-fold of 
COX-2 protein activity over the control (lane 1). Other treatments including PMA (lane 
3), sorbitol (lane 4), H2O2 (lane 6), or combinations of these agents, such as PMA plus 
sorbitol (lane 5) or PMA plus H2O2 (lane 7), did not increase COX-2 protein activity. 
These results indicate that high activity of COX-2 protein by LPS treatment results from 
high level o f COX-2 mRNA expression shown in Figure 7C. Similarly, COX-2 protein 
and COX-2 mRNA were not observed after treatment with PMA, sorbitol, H2O2, or 
combinations of these agents.
Combined with data from Figure 7A to 7D, these results suggest the following 
things: (1) activation of MAPKs by PMA, sorbitol, H2O2, or combinations of these 
agents is insufficient to induce COX-2 mRNA expression in RAW 264.7 cells. (2) 
LPS-induced activation of MAPKs (ERK-I, ERK-2, P38 MAP kinase, and JNK-1)
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occurring within minutes is accompanied in LPS-induced expression of COX-2 mRNA 
and protein occurring after several hours in RAW 264.7 cells stimulated with LPS. (3) 
LPS-induced activation of MAPKs (ERK-1, ERK-2, P38, and JNK-1) alone is likely to 
be insufficient to induce the expression of COX-2 mRNA and protein, suggesting that 
there are additional signaling pathways activated by LPS leading to the expression of 
COX-2 in LPS-stimulated RAW 264.7 cells.
To examine whether activation of NF-kB is involved in the expression of COX- 
2, the same samples used for Figure 7A, and 7B were analyzed by an IkB-a immunoblot 
analysis using an anti-IkB-a antibody. Since NF-kB activation correlates with rapid 
proteolytic degradation of IkB-a protein, this experiment reveals that the degradation of 
IkB-a protein by agonists indicates NF-kB activation. The results of IkB-a western blot 
analysis are shown in Figure 7E. Only LPS treatment (lane 2) resulted in complete 
degradation of IkB-a protein in RAW 264.7 cells, indicating NF-kB activation by LPS. 
However, the treatments of PMA (lane 3), sorbitol (lane 4), H2O2 (lane 6), or 
combinations of PMA plus sorbitol (lane 5) or PMA plus H2 O2 (lane 7) did not induce 
degradation of IkB-a protein in RAW 264.7 cells.
These results indicate that LPS is a potent inducer o f NF-kB activation in RAW
264.7 cells, but PMA, sorbitol, H2O2, or combinations of these agents are not activators 
o f NF-kB in RAW 264.7 cells. These results suggest that rapid activation o f NF-kB 
induced by LPS within minutes is accompanied in the expression o f COX-2 occurring 
after several hours in LPS-stimulated RAW 264.7 cells.
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3.1.2. Partial Inhibition of MAPKs (ERK-1, ERK-2, and P38) by PD98059 and 
SB203580 caused Partial Suppression of COX-2 Expression in LPS-stimulated 
RAW 264.7 Cells
MEK-1 and MEK-2 are the upstream activators that phosphorylate and activate 
ERK-1 and ERK-2 in most cell types. PD98059 selectively inhibits the kinase activity 
of MEK-1 and MEK-2 (Pang et al., 1995), leading to inactivation of ERK-1 and ERK-2. 
Using PD98059, the current study examined whether inhibition of ERK-1 and ERK-2 
causes the suppression of COX-2 expression in LPS-stimulated RAW 264.7 cells.
RAW 264.7 cells were pretreated with PD98059 in different concentrations (0,
1,10, 50,100, and 200 pM) for 1 hour, and washed with DMEM containing 1 % 
antibiotic (penicillin/streptomycin) twice. Cells were then treated with 1 pg/ml of LPS 
plus PD98059 in the same concentrations used in pretreatment for 30 minutes. Cell 
lysates were analyzed by in-gel protein kinase assay to measure the kinase activity of 
ERK-1 and ERK-2. For in-gel ERK-1 and ERK-2 kinase assay, myelin basic protein 
(MBP) was used as a general exogenous substrate of ERK-1 and ERK-2 with [y-P32] 
ATP. The extent of incorporated y-P32 in MBP by ERK-1 and ERK-2 was used as an 
indication o f ERK-1 and ERK-2 kinase activity. Cells were also treated with LPS plus 
PD98059 in the same concentrations used in in-gel ERK-1 and ERK-2 kinase assay for 
8 hours to perform RIA in order to measure the amount o f PGE2. The amount of PGE2  
was used as an indication of COX-2 protein activity. For RIA, 30 pM of arachidonic 
acid as an exogenous substrate o f COX-2 was added to cells incubated for 8 hours.
The results o f an in-gel kinase assay showed that LPS-induced kinase activity of 
ERK-1 and ERK-2 was inhibited by PD98059 treatment in a concentration-dependent 
manner in LPS-stimulated RAW 264.7 cells as assessed by the decreased extent of
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incorporated y-P32 in MBP by ERK-1 and ERK-2 (Figure 8A). The results o f RIA 
showed that LPS-induced COX-2 enzyme activity was decreased by PD98059 treatment 
in a concentration-dependent manner in LPS-stimulated RAW 264.7 cells as assessed 
by the decreased amount of PGE2 (Figure 8B). These results indicate that the inhibition 
of LPS-induced activation of ERK-1 and ERK-1 by PD98059 treatment resulted in an 
inhibition o f LPS-induced COX-2 enzyme activity, suggesting that LPS-induced 
activation o f ERK-1 and ERK-1 appears to be in part involved in the regulation of LPS- 
induced COX-2 protein activity in RAW 264.7 cells.
However, the treatment of PD98059 did not affect LPS-induced tyrosine 
phosphorylation of P38 MAP kinase as measured by anti-phosphotyrosine 
immunoblotting analysis using an anti-P38 antibody (Figure 8C). Furthermore, 
PD98059 treatments did not affect LPS-induced activation of JNK-1 as measured by an 
JNK-1 western blotting analysis using anti-JNK-1 antibody (Figure 8D), and by an in­
gel JNK-1 kinase assay using ATF2 as an exogenous substrate of JNK-1 with [y-P32] 
ATP (Figure 8E). These results indicate that inhibition of LPS-induced activation of 
ERK-1 and ERK-2 is independent from that of LPS-induced activation of P38 MAP 
kinase or JNK-1 in LPS-stimulated RAW 264.7 cells. These observations lead to the 
suggestion that inhibition of LPS-induced activation o f P38 and/or JNK-1 appears to be 
involved in regulation of COX-2 expression in LPS-stimulated RAW 264.7 cells.
SB203580, a pyridinyl-imidazole compounds, inhibits CSBP [CSAID (cytokine- 
suppressive anti-inflammatory drug) binding protein], which is identified as P38 MAP 
kinase homologue (Lee et al., 1993). Using SB203580, the current study examined
68
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 8. Inhibition of the ERK-1 and ERK-2 activity and reduction of PGE2 
levels by PD98059 in RAW 264.7 cells.
(A) ERK-1 and ERK-2 in-gel kinase assay (panel A). RAW 264.7 cells were pretreated 
with PD98059 in the indicated concentrations for 1 hour, and then stimulated with LPS 
(1 pg/ml) plus PD98059 in the same concentrations as pretreatment for 30 minutes. 
Solubilized proteins were analyzed by an in-gel kinase assay using myelin basic protein 
(MBP) as a  substrate of ERK-1 and ERK-2 with [y-P32] adenosine triphosphate (ATP). 
The extent of incorporated y-P32 in MBP was used as an assessment of the activity of 
ERK-1 and ERK-2.
(B) Radioimmunoassay (RIA) (panel B). RAW 264.7 cells were treated with the 
indicated agent for 8 hours, and then arachidonic acid (30 pM) as a substrate of COX-2 
was added to the cells for 10 minutes. The conditioned culture media was removed and 
analyzed by RIA to measure the amounts of PGE2  produced by COX-2. The amounts of 
PGE2 measured by RIA were used as an assessment of COX-2 activity.
(C) Anti-phosphotyrosine immunoblot analysis (panel C) of the same samples used in 
panel A using an anti-phosphotyrosine antibody (4G10). P38-P, phosphorylated P38.
(D) JNK-1 western blot analysis (panel D) of the same samples used in panel A using an 
anti-JNK-1 antibody. JNK-1, nonphosphorylated JNK-1; JNK-l-P, phosphorylated 
JNK-1.
(E) JNK-1 in-gel kinase assay (panel E). To measure JNK-1 kinase activity, the same 
samples and procedures in panel A were used except the use o f ATF2 as a substrate of 
JNK-1 instead of MBP. The extent o f incorporated y-P32 in ATF2 was used as an 
assessment of the activity of JNK-1.
Panel B, C, and D are derived from Hwang, 1997.
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whether inhibition of P38 MAP kinase causes the suppression of COX-2 expression in 
LPS-stimulated RAW 264.7 cells. RAW 264.7 cells were pretreated with SB203580 in 
different concentrations (0, 0.05,0.25,1.25, 6.25, 12.5, and 37.5 pM) for 1 hour, and 
washed with DMEM containing 1 % antibiotic (penicillin/streptomycin) twice. Cells 
were then treated with 1 pg/ml of LPS plus SB203580 in the same concentrations used 
in pretreatment for 30 minutes. Cell lysates were analyzed by anti-phosphotyrosine 
immunoblotting analysis after immunoprecipitation with an anti-P38 antibody. RAW
264.7 cells were also treated withl pg/ml of LPS plus SB203580 in different 
concentrations (0,0.05, 0.25,1.25, 6.25,12.5, and 37.5 pM) for 8 hours to perform 
COX-2 western blotting analysis to measure the level of COX-2 protein affected by 
SB203580 treatment.
The results of anti-phosphotyrosine immunoblot analysis after P38 
immunoprecipitation showed that LPS-induced tyrosine phosphorylation of P38 MAP 
kinase was decreased by SB203580 treatment in a concentration-dependent manner in 
LPS-stimulated RAW 264.7 cells (Figure 9A). The results of COX-2 western blot 
analysis showed that LPS-induced COX-2 protein expression was decreased by 
SB203580 treatment in a concentration-dependent manner in LPS-stimulated RAW
264.7 cells (Figure 9B). However, the level o f GAPDH protein, an internal control, was 
not affected by SB203580 treatment in all lanes as shown in Figure 9B. These results 
indicate that inhibition of LPS-induced activation o f  P38 MAP kinase by SB203580 
treatment resulted in an inhibition of LPS-induced COX-2 protein expression, 
suggesting that LPS-induced activation of P38 MAP kinase may contribute to the 
regulation o f LPS-induced COX-2 protein expression in RAW 264.7 cells.
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Figure 9. Inhibition of tyrosine phosphorylation of P38 MAP kinase and partial 
inhibition of COX-2 expression by SB203580 in RAW 264.7 cells.
(A) P38 immunoprecipitation and anti-phosphotyrosine immunoblot analysis (panel A). 
RAW 264.7 cells were pretreated with SB203580 in the indicated concentrations for 1 
hour, and then stimulated with LPS (1 pg/ml) plus SB203580 in the same 
concentrations as pretreatment for 30 minutes. Solubilized proteins (500 pg) were 
immunprecipitated with an anti-P38 antibody and the immunoprecipitates were detected 
by an anti-phosphotyrosine antibody (4G10). P38-P, phosphorylated P38.
(B) COX-2 and GAPDH western blot analysis (panel B). RAW 264.7 cells were treated 
with LPS (1 pg/ml) plus SB203580 in the indicated concentrations for 8 hours without 
pretreatment, and then solubilized proteins were detected by anti-COX-2 and anti- 
GAPDH antibodies in a same membrane.
(C) JNK-1 western blot analysis (panel C) o f the same samples used in panel A using an 
anit-JNK-1 antibody. JNK-1, nonphosphorylated JNK-1; JNK-1-P, phosphorylated 
JNK-1.
Panel A and B are derived from Hwang, 1997.
72
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LPS - + +  + + + + +
(l|ig/ml)
SB 203580 - - 0.05 0.25 1.25 6.25 12.5 37.5
(pM)
kDa 
-50 
■^“ Heavy IgG
Panel B
-77
‘COX-2
GAPDH
Panel C
-50.6 
JNK-1-P 
JNK-1
73
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3.1.3. The Inhibition of NF-kB Activation by Z-LLF-CHO caused the Suppression 
of COX-2 Expression in LPS-stimulated RAW 264.7 Cells without Affecting LPS- 
induced Tyrosine Phosphorylation of MAPKs
DiDonato et al. (1995) used various multicatalytic protease complex (MPC) 
inhibitors, including Z-LLF-CHO (benzyloxy-carbonyl-Leu-Leu-phenylalaninal), to 
demonstrate that the degradation of IkB-a is required for NF-kB activation. Using Z- 
LLF-CHO, the current study tested whether the inhibition of NF-kB results in the 
suppression of COX-2 expression in LPS-stimulated RAW 264.7 cells.
A time course study with LPS (1 pg/ml) was performed to determine when LPS 
treatment causes the maximal degradation of IkB-a (an indication of NF-kB activation) 
in RAW 264.7 cells. RAW 264.7 cells were treated without or with LPS for different 
time periods (0, 1,5,10,20, 30, 60, or 120 minutes). RAW 264.7 cells were also 
pretreated with Z-LLF-CHO in different concentrations (0, 1, 5, or 20 |^M) for 1 hour, 
and then treated with LPS (1 jag/ml) plus Z-LLF-CHO in the same concentrations used 
in pretreatment for 30 minutes. Cell lysates were analyzed by western blot analysis for 
IkB-a using anti-IkB-a antibody.
The results of IkB-a western blot analysis demonstrated a dramatic degradation 
of IkB-a protein at 20 minute after LPS treatment. Maximal degradation of IkB-a 
protein occurred at 30 minutes after LPS treatment in RAW 264.7 cells (Figure 10A). 
However, the degradation of IkB-a protein induced by LPS treatment was transient 
because IkB-a protein was fully recovered at 60 minutes after LPS treatment. These 
results suggest that LPS-induced NF-kB activation appears to be a rapid and transient 
event in LPS-stimulated RAW 264.7 cells.
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Figure 10. Inhibition of LPS-induced degradation of IkB-a and LPS-induced 
expression of COX-2 by Z-LLF-CHO in RAW 264.7 cells.
(A) IkB-a western blot analysis (panel A and B). For panel A, RAW 264.7 cells were 
treated with LPS (1 pg/ml) for the indicated time periods, and solubilized proteins were 
detected by an anti-IkB-a antibody. For panel B, RAW 264.7 cells were pretreated with 
Z-LLF-CHO in the indicated concentrations for 1 hour, and then stimulated with LPS (1 
|ig/ml) plus Z-LLF-CHO in the same concentrations as pretreatment for 30 minutes. 
Solubilized proteins were detected by an anti-IkB-a antibody. IkB-a, 
nonphosphorylated IkB-a; IkB-a-P, phosphorylated IkB-a.
(B) COX-2 and GAPDH western blot analysis (panel C). RAW 264.7 cells were treated 
with LPS (1 |ig/ml) plus Z-LLF-CHO in the indicated concentrations for 8 hours 
without pretreatment, and then solubilized proteins were detected by anti-COX-2 and 
anti-GAPDH antibodies in a same membrane.
(C) Anti-phosphotyrosine immunoblot analysis (panel D) of the same samples used in 
panel B using an anti-phosphotyrosine antibody (4G10).
Panel B and C are derived from Hwang, 1997.
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Figure 10B showed that LPS-induced NF-kB activation (as assessed by degradation of 
IkB-a protein) was inhibited by Z-LLF-CHO treatment in a concentration-dependent 
manner in LPS-stimulated RAW 264.7 cells. The inhibition of LPS-induced NF-kB 
activation by Z-LLF-CHO treatment resulted in the inhibition of LPS-induced COX-2 
protein expression in a concentration-dependent manner in LPS-stimulated RAW 264.7 
cells (Figure IOC). These results suggest that LPS-induced NF-kB activation may be 
involved in LPS-induced COX-2 expression in RAW 264.7 cells.
Z-LLF-CHO treatment, however, did not affect LPS-induced tyrosine 
phosphorylation of ERK-1, ERK-2, and P38 MAP kinase as measured by anti- 
phosphotyrosine immunoblot analysis (Figure 10D), suggesting that inhibition of LPS- 
induced NF-kB activation is independent from that of LPS-induced activation of 
MAPKs (ERK-1, ERK-2, and P38 MAP kinase).
3.1.4. Both Inhibition of LPS-induced Activation of MAPKs and NF-kB by 
Radicicol or Herbimycin A resulted in the Suppression of COX-2 Expression in 
LPS-stimulated RAW 264.7 Cells
Radicicol is an inhibitor o f p60v'sre (Kwon et al., 1992) and Herbimycin A is a 
protein tyrosine kinase (PTK) inhibitor (Fukazawa et al., 1991). Herbimycin A also 
inhibits IL-la-induced NF-kB activation (Iwasaki et al., 1992). It has been 
demonstrated that these PTK inhibitors suppress the expression of COX-2 in LPS- 
stimulated rat alveolar macrophages (Chanmugam et al., 1995) and RAW 264.7 cells 
(Gang, 1996). Using Radicicol or Herbimycin A, we examined whether both inhibition 
of LPS-induced activation of MAPKs and NF-kB result in the suppression of COX-2 
expression in LPS-stimulated RAW 264.7 cells.
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RAW 264.7 cells were pretreated with different concentrations of Radicicol (0, 
0.001, 0.1, or 1 (ig/ml) or Herbimycin A (0.5 |ig/ml) for 3 hours, and then treated with 
LPS (1 fig/ml) plus Radicicol or Herbimycin A in the same concentrations used in 
pretreatment for 30 minutes. Cell lysates were prepared and analyzed by in-gel kinase 
assay for ERK-1, ERK-2 or JNK-l, western blot analysis, or immunoprecipitation. For 
COX-2 western blot analysis, RAW 264.7 cells were also treated with LPS (1 pg/ml) 
plus Radicicol or Herbimycin A for 8 hours.
Figure 11A showed that LPS-induced activation of ERK-1 and ERK-2 was 
inhibited by Radicicol treatment in a concentration-dependent manner as measured by 
in-gel ERK-1 & ERK-2 kinase assays using MBP as a general exogenous substrate. The 
treatment o f 0.5 |ig/ml o f Herbimycin A weakly inhibited LPS-induced kinase activity 
of ERK-1 and ERK-2 (Figure 11 A). The same samples used in Figure 11A were also 
immunoprecipitated with an anti-P38 antibody and then the immunoprecipitates were 
analyzed by anti-phosphotyrosine immunoblot analysis with an anti-phosphotyrosine 
antibody (4G10). Figure 1 IB showed that LPS-induced tyrosine phosphorylation of P38 
MAP kinase was inhibited by Radicicol and Herbimycin A in a concentration-dependent 
manner. Figure 11C showed that LPS-induced activation of JNK-1 was inhibited by 
Radicicol and Herbimycin A in a concentration-dependent manner as measured by JNK- 
1 western blot analysis using an anti-JNK-1 antibody. These results indicate that 
Radicicol or Herbimycin A inhibit LPS-induced activation of MAPKs (ERK-1, ERK-2, 
P38 MAP kinase, or JNK-1) in RAW 264.7 cells.
Figure 1 ID showed that LPS-induced degradation of IkB-a was also inhibited 
by Radicicol and Herbimycin A as measured by IkB-a western blot analysis with an
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Figure 11. Inhibition of LPS-induced activation of MAPKs, degradation of IkB- 
a , and expression of COX-2 by Radicicol and Herbimycin A in RAW 264.7 cells.
(A) ERK-1 and ERK-2 in-gel kinase assay (panel A). RAW 264.7 cells were pretreated 
with Radicicol and Herbimycin A in the indicated concentrations for 3 hours, and then 
stimulated with LPS (1 pg/ml) plus these inhibitors in the same concentrations as 
pretreatment for 30 minutes. Solubilized proteins were analyzed by an in-gel kinase 
assay using myelin basic protein (MBP) as a substrate of ERK-1 and ERK-2 with [y-P32] 
adenosine triphosphate (ATP). The extent o f incorporated y-P32 in MBP was used as an 
assessment of the activity of ERK-1 and ERK-2.
(B) P38 immunoprecipitation and then anti-phosphotyrosine immunoblot analysis 
(panel B). Solubilized proteins (500 pg) used in panel A were immunprecipitated with 
an anti-P38 antibody and then the immunoprecipitates were detected by an anti- 
phosphotyrosine antibody (4G10). P38-P, phosphorylated P38.
(C) JNK-1 western blot analysis (panel C) of the same samples used in panel A using an 
anit-JNK-1 antibody. JNK-1, nonphosphorylated JNK-1; JNK-1 -P, phosphorylated 
JNK-1.
(D) IkB-a western blot analysis (panel D) o f the same samples used in panel A  using an 
anti-IkB-a antibody.
(E) COX-2 and GAPDH western blot analysis (panel E). RAW 264.7 cells were treated 
with LPS (1 pg/ml) plus these inhibitors in the indicated concentrations for 8 hours 
without pretreatment, and then solubilized proteins were detected by anti-COX-2 and 
anti-GAPDH antibodies in a same membrane.
Panel A, B, C, D, and E are derived from Hwang, 1997.
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anti-IkB-a antibody. This result indicates that Radicicol or Herbimycin A inhibit NF- 
kB activation by blocking LPS-induced degradation of IkB-a protein in RAW 264.7 
cells. Figure 1 IE showed that the expression of COX-2 in LPS-stimulated RAW 264.7 
cells was inhibited by the treatment o f Radicicol and Herbimycin A as measured by 
COX-2 western blot analysis.
These results indicate that both inhibition of MAPKs and NF-kB by Src PTK 
inhibitors such as Radicicol and Herbimycin A resulted in the suppression of COX-2 
expression in LPS-stimulated RAW 264.7 cells. These results suggest that LPS-induced 
activation of MAPKs and NF-kB may be involved in LPS-induced COX-2 expression in 
RAW 264.7 cells.
3.2. Examination of the Role of Lyn on COX-2 Expression
3.2.1. Overexpression of Mutant Lyn results in High Expression of COX-2 in 
NIH/3T3 Cells Transfected with Mutant lyn cDNA
It has been demonstrated that Radicicol treatment inhibits the expression of 
COX-2 as well as the tyrosine phosphorylation and protein level of Lyn in LPS- 
stimulated rat alveolar macrophages (Chanmugam et al., 1995). Lyn is one of Src- 
family protein tyrosine kinases (PTKs) and predominantly expressed in macrophages. 
This observation suggests that Src-family PTKs may play an important role in LPS- 
mediated signaling pathways leading to the expression of COX-2 in LPS-stimulated 
macrophages.
Xie et al. (1991) have reported that the expression of many immediate early 
genes, including COX-2 gene, are induced in Rous sarcoma virus (RSV)-infected 
chicken embryo fibroblasts (CEF) in which v-Srcp60 was constitutively overexpressed.
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v-Src is a mutant that one amino acid (tyrosine) at the C-terminal regulatory domain in 
c-Src protein was mutated with another amino acid (phenylalanine). It suggests that 
COX-2 expression be induced by an amino acid change at the C-terminal regulatory 
domain in other Src-family PTKs.
Using wild type lyn DNA and mutant lyn DNA in which the tyrosine residue at 
the C-terminal regulatory domain of Lyn was replaced with phenylalanine, the current 
study examined whether overexpression of mutant Lyn alone induces COX-2 expression 
in mutant lyn DNA-transfected NIH/3T3 cells.
After transfection, the expression level of Lyn was determined in wild type and 
mutant lyn DNA-transfected cells. Figure 12A showed that wild type (lane 2) and 
mutant Lyn (lane 3) were highly expressed in <$NX cells as measured by Lyn western 
blot analysis. There was no expression of Lyn in the control (pBPSTRl vector alone, 
lane 1) as shown in Figure 12A. Because of the attached Flag DNA sequence encoding 
8 amino acids (Asp-Tyr-Asp-Asp-Asp-Asp-Lys) at the C-terminus of lyn DNA cloned 
in pBPSTRl vector, Lyn is expressed as a Lyn-Flag (epitope) fusion protein in 
transfected cells. Anti-Flag antibody was applied to detect the expression o f Flag- 
tagged Lyn and to avoid the detection of any endogenous Lyn protein present in cells. 
Figure 12B showed that the expression of Flag was determined by an anti-Flag antibody 
in wild type (lane 2) and mutant Lyn (lane 3) in <DNX cells, whereas there was no Flag 
expressed in the control (pBPSTRl vector alone, lane 1). These results indicate that lyn 
DNAs were appropriately transfected to ONX cells. Figure 12C and 12D showed that 
the high expression of wild type (lane 2) and mutant (lane 3) Flag-tagged Lyn p56 was
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Figure 12. Detection of the expression of wild type and mutant Flag (epitope)- 
tagged Lyn kinases in transfected Phoenix cells and infected NIH/3T3 cells with 
wild type and mutant lyn cDNA.
(A) Lyn or Flag western blot analysis (panel A, B, C, and D). For panel A, Phoenix 
cells were transfected with a retroviral expression vector pBPSTRl alone, or pBPSTRl 
vectors containing wild type and mutant Flag-tagged lyn DNA. After 48 hour post­
transfection, the culture media containing infectious viral particles produced by Phoenix 
cells was removed, filtered, and used to infect NIH/3T3 cells. Phoenix cells were lysed 
and solubilized proteins were detected by an anti-Lyn antibody. Lynp56, 56 kDa form of 
Lynp53/56. For panel B, the same samples used in panel A were detected by an anti-Flag 
antibody. For panel C, NIH/3T3 cells were infected with viral particles for 24 hours, 
and selected in the presence of an antibiotic puromycin (2 pg/ml). Selected NIH/3T3 
cells were lysed and solubilized proteins were detected by an anti-Lyn antibody. For 
panel D, the same samples used in panel C were detected by an anti-Flag antibody.
Lane 1, pBPSTRl vector alone; lane 2, wild type Flag-tagged lyn DNA-pBPSTRl; lane 
3, mutant Flag-tagged lyn DNA-pBPSTRl.
(B) Flag immunoprecipitation and then Lyn western blot analysis (panel F). Samples 
used in panel C were immunoprecipitated with an anti-Flag antibody and then the 
immunoprecipitates were detected by an anti-Lyn antibody. Lane 1, pBPSTRl vector 
alone; lane 2, wild type Flag-tagged lyn DNA-pBPSTRl; lane 3, mutant Flag-tagged lyn 
DNA-pBPSTRl.
(C) Immune-complex Lyn kinase assay (panel F). The same samples used in panel C 
were immunoprecipitated with an anti-Lyn antibody, and the immunoprecipitates were 
analyzed by an immune-complex kinase assay using an acid-denatured enolase (9 
pg/reaction) as a general substrate of Src kinases with [y-P32] (10 pCi/reaction). The 
extent of incorporated y-P32 in enolase was used as an assessment of Lyn kinase activity. 
Lyn-P, phosphorylated Lyn; enolase-P, phosphorylated enolase. Lane 1, wild type Flag- 
tagged Lyn in the presence of enolase; lane 2, wild type Flag-tagged Lyn in the absence 
o f enolase; lane 3, mutant Flag-tagged Lyn in the presence of enolase; lane 4, mutant 
Flag-tagged Lyn in the absence of enolase.
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determined by anti-Lyn or anti-Flag antibodies in infected NIH/3T3 cells, respectively. 
Figure 12E confirmed the high expression of wild type (lane 2) and mutant (lane 3) 
Flag-tagged Lyn p56 in infected NIH/3T3 cells by Lyn western blotting analysis after 
immunoprecipitation with anti-Flag antibody.
After determining the high expression of wild type and mutant Lynp56 in 
infected NIH/3T3 cells, the kinase activity of wild type and mutant Lynp56 was 
determined by an immunocomplex kinase assay. The immunocomplex-Lyn kinase 
assay was performed using the immunoprecipitates with an anti-Lyn antibody and [y- 
P32] ATP in the absence or presence o f acid-denatured enolase as a general exogenous 
substrate of Lyn. The extent of incorporated y-P32 in Lynp56 was assessed as the degree 
of autophosphorylation on tyrosine residue in Lynp56. The extent of incorporated y-P32 
in enolase by Lynp56 was assessed as an indication of Lyn kinase activity. Figure 12F 
showed that the degree of autophosphorylation of wild type Lynp56 (lane 1-enolase, and 
lane 2-no enolase) was much higher than that of mutant Lynp56 (lane 3-enolase, and 
lane 4-no enolase) in infected NIH/3T3 cells. Figure 12F also exhibited that the more 
autophosphorylated wild type Lynp56 (lane 1) showed increased phosphorylation of 
enolase, whereas less autophophorylated mutant Lynp56 did not phosphorylate enolase, 
suggesting less kinase activity o f mutant Lyn pS6. These results suggest that high 
autophosphorylation o f wild type Lyn p56 might be resulted from high expression level 
of wild type Lynp56, whereas less autophosphorylation of mutant Lynp56 might be 
resulted from low expression level o f mutant Lynp56.
Figure 13 A and 13B showed that overexpression of mutant Lyn p56 (lane 3) 
induced much higher expression of COX-2 (about 4-fold) than that of wild type Lyn p56
85
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 13. High COX-2 expression and production of PGE2 levels induced by 
overexpression of mutant Lyn kinase in N1H/3T3 cells.
(A) COX-2 western blot analysis and immunoprecipitation (panel A and B). For panel 
A, infected and selected NIH/3T3 cells were lysed and solubilized proteins were 
analyzed by COX-2 immunoblot. The same samples used in panel A were 
immunoprecipitated with an anti-COX-2 antibody and then the immunoprecipitates 
were analyzed by COX-2 immunoblot (panel B). Lane 1, pBPSTRl vector alone; lane 
2, wild type Flag-tagged lyn DNA-pBPSTRl; lane 3, mutant Flag-tagged lyn DNA- 
pBPSTRl.
(B) Radioimmunoassay (RIA) (panel C). Infected and selected NIH/3T3 cells (about 1 
x 106) were grown in DMEM supplemented with 1 % (v/v) penicillin/streptomycin and 
10 % (v/v) heat-inactivated FBS for 24 hours, and then arachidonic acid (30 pM) as a 
substrate of COX-2 was added to cells for 10 minutes. The conditioned media was 
removed and analyzed by RIA to measure the amounts of PGE2 produced by COX-2. 
The amounts of PGE2 measured by RIA were assessed as an indication of COX-2 
activity. Lane 1, pBPSTRl vector alone; lane 2, wild type Flag-tagged lyn DNA- 
pBPSTRl; lane 3, mutant Flag-tagged lyn DNA-pBPSTRl.
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(lane 2) in infected N1H/3T3 cells as measured by COX-2 western blot analysis and 
immunoprecipitation. These results indicate that overexpression of mutant Lynp56 is 
sufficient to induce the expression of COX-2 in infected NIH/3T3 cells.
To determine whether high expression level of COX-2 induced by 
overexpression of mutant Lynp56 reflects high COX-2 enzyme activity in infected 
NIH/3T3 cells, RIA was performed to measure the amount of PGE2  produced by COX- 
2. The amount of PGE2 was used as an indication of COX-2 enzyme activity. Figure 
13C showed that the highest production of PGE2 was detected in mutant lyn DNA- 
transfected NIH/3T3 cells (lane 3). This result indicates that a high expression level of 
COX-2 protein induced by overexpression of mutant Lynp56 reflects a high COX-2 
enzyme activity, leading to increased production of PGE2. Figure 13C also displayed 
that there was no difference of COX-2 enzyme activity in the control (lane 1) and wild 
type Lynp56 (lane 2). This result indicates that a low expression level of COX-2 
detected in wild type lyn DNA-infected NIH/3T3 cells (Figure 13 A, and 13B) might be 
resulted from the basal level of COX-2 protein present in these cells or the result of 
other effects, such as serum in the culture media.
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CHAPTER 4 
DISCUSSION
A number of signaling pathways have been implicated in LPS responses in 
macrophages. The mitogen-activated protein kinases [MAPKs; extracellular signal- 
regulated kinases (ERKs), P38 MAP kinase, and c-jun N-terminal kinases (JNKs)], 
nuclear factor kappa B (NF-kB), and Lyn kinase are known to be activated in the early 
stages (within minutes) of LPS signaling pathways. The current study shows the 
following: 1) LPS-induced activation of MAPKs and NF-kB may be involved in the 
expression of COX-2 in LPS-stimulated RAW 264.7 macrophages; 2) Overexpression 
of mutant Lynp56 results in high expression of COX-2 and high production of PGE2 in 
mutant lyn DNA-transfected NIH/3T3 cells.
LPS treatment results in rapid phosphorylation of MAPKs; ERK-1, ERK-2, P38 
MAP kinase (Weinstein et al., 1991, 1992; Han et al., 1993; Gang, 1996), and JNK 
(Hambleton et al., 1996). It has been shown that the LPS-induced phosphorylation of 
MAPKs reflects their kinase activities (Davis, 1994; Hambleton et al., 1996; Hwang et 
al., 1997). Increased protein phosphorylation is a rapid LPS-activated signaling event 
that may mediate release of arachidonic acid metabolites (e.g. PGE2) in LPS-stimulated 
RAW 264.7 cells (Weinstein et al., 1991).
The expression o f COX-2 is selectively induced by LPS treatment after several 
hours in rat alveolar macrophages (Lee et al., 1992; Chanmugam et al., 1995) and RAW
264.7 macrophages (Gang, 1996). Chanmugam et al. (1995) indicated that maximum 
phosphorylation occurs much earlier than maximum expression o f COX-2 mRNA and 
protein in LPS-stimulated rat alveolar macrophages. These observations suggest that
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rapid LPS-induced activation of MAPKs (within minutes) may be relevant to LPS- 
induced expression of COX-2 after several hours in LPS-stimulated macrophages. In 
the current study, it was first examined whether rapid LPS-induced activation of 
MAPKs (particularly ERK-1, ERK-2, or P38 MAP kinase) might be involved in LPS- 
induced expression of COX-2 in RAW 264.7 cells.
MEK-1 and MEK-2 are the immediate upstream protein kinases that 
phosphorylate and activate ERK-1 and ERK-2, respectively. PD98059 is an inhibitor of 
phosphorylation and kinase activity o f MEK-1 and MEK-2 (Pang et al., 1995). Using 
PD98059, the current study examined whether inhibition of ERK-1 and ERK-2 can 
regulate COX-2 expression in LPS-stimulated RAW 264.7 cells.
PD98059 treatment that inhibited the kinase activity of ERK-1 and ERK-2 
following LPS treatment in a concentration-dependent manner (Figure 8A) resulted in 
partial reduction of PGE2 production in a concentration-dependent manner in LPS- 
stimulated RAW 264.7 cells (Figure 8B). Similarly, PD98059 treatment caused partial 
inhibition of COX-2 expression in LPS-stimulated RAW 264.7 cells (Hwang et al., 
1997). This partial inhibition of COX-2 protein expression following PD98059 
treatment was correlated with the partial reduction of PGE2 levels by PD98059 
treatment in LPS-stimulated RAW 264.7 cells. These results suggest that inhibition of 
ERK-1 and ERK-2 may be involved in the suppression of COX-2 expression, which 
leads to the partial inhibition of COX-2 enzyme activity and PGE2 production. The 
treatment o f PD98059, however, does not affect LPS-induced tyrosine phosphorylation 
o f P38 MAP kinase (Figure 8C) and LPS-induced electrophoretic mobility shift o f JNK- 
1 (Figure 8D) following LPS stimulation in RAW 264.7 cells. These results suggest
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that the regulatory mechanism of P38 MAP kinase and/or JNK-1 is independent from 
thatofERK-1 andERK-2.
The production of inflammatory cytokines including interleukin 1 (IL-1) and 
tumor necrosis factor (TNF) from LPS-stimulated human monocytic cell line (THP1) is 
inhibited by a new series of pyridinyl-imidazole compounds. SB203580, one of 
pyridinyl-imidazole compounds, inhibits the kinase activity of a cytokine-suppressive 
anti-inflammatory drug (CSAID) binding protein, which is identified as a P38 MAP 
kinase homologue (Lee et al., 1993). Recently, Guan et al. (1997) demonstrated that the 
pharmacological inhibition of P38 MAP kinase by SC68376, another inhibitor of P38 
MAP kinase, results in the inhibition of cytokine-induced stimulation of COX-2 and 
PGE2 production. This suggests that the signaling pathway of P38 MAP kinase may be 
one of the important signaling mechanisms modulating the expression of COX-2 and 
PGE2 production induced by various agonists including LPS. Using SB203580, we 
tested whether the inhibition of P38 MAP kinase might result in the suppression of 
COX-2 expression in LPS-stimulated RAW 264.7 cells.
SB203580 treatment that inhibited tyrosine phosphorylation of P38 MAP kinase 
following LPS stimulation (Figure 9A) also resulted in partial suppression of COX-2 
protein expression in LPS-stimulated RAW 264.7 cells (Figure 9B). Similarly, 
SB203580 treatment partially reduced PGE2 levels in LPS-stimulated RAW 264.7 cell 
(Hwang et al., 1997). This change of COX-2 protein expression following SB203580 
treatment was correlated with the partial reduction o f PGE2 production by SB203580 
treatment in LPS-stimulated RAW 264.7 cells. These results indicate that the inhibition 
o f P38 MAP kinase may be involved in the suppression o f COX-2 protein expression,
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which leads to the partial reduction of PGE2 levels. This suggests that P38 MAPK is an 
important regulator in COX-2 expression by LPS in RAW cells. It is supported by the 
recent results by Dean et al., (1999) in which COX-2 mRNA stability and transcription 
in LPS-stimulated human monocytes is regulated by P38 MAPK using SB 203580. 
Using SB 203580, Ridley et al., (1997) also demonstrated the regulatory role of P38 
MAPK on COX-2 expression induced by IL-1 in human fibroblasts. Using another P38 
inhibitor, SC68376, Guan et al., (1997) suggested that p38 MAPK plays an important 
role in IL-1 beta signaling mechanism, which mediates the up-regulation of 
prostaglandin synthesis in glomerular mesangial cells.
As mentioned previously, LPS treatment rapidly activates MAPKs by a 
phosphorylation event and the increased protein phosphorylation is a rapid LPS- 
activated signaling event that can mediate release of arachidonic acid metabolites in 
LPS-stimulated RAW 264.7 cells. Based on this information, it was reasonable to 
postulate whether the LPS-induced activation of MAPKs alone might be sufficient to 
lead to COX-2 expression in LPS-stimulated RAW 264.7 cells.
It has been shown that phorbol myristate acetate (PMA) is an activator of ERK-1 
and ERK-2, and sorbitol is an activator of P38 MAP kinase in mammalian cells (Han et 
al., 1994). The treatment of hydrogen peroxide (H2O2 ) results in phosphorylation of 
several subfamilies o f MAPKs. Using these known activators of MAPKs, the current 
study further examined whether the activation of MAPKs alone might be sufficient to 
induce COX-2 expression and PGE2  production in RAW 264.7 cells.
The treatment of PMA, sorbitol, H2O2, or combinations o f these agents that 
resulted in the phosphorylation o f MAPKs (Figure 1A and IB, lanes 3,4, 5,6, and 7,
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respectively) failed to induce COX-2 mRNA expression (Figure 7C) and PGE2 
production (Figure 7D) in RAW 264.7 cells. However, LPS treatment results in high 
phosphorylation of MAPKs (Figure 7A and 7B, lane 2) as well as high expression of 
COX-2 mRNA (Figure 7C, lane 2) and high amounts of PGE2 levels (Figure 7D, lane 2) 
in RAW 264.7 cells. Our results indicate that the LPS-induced activation of MAPKs 
alone is insufficient to induce COX-2 expression and PGE2 production in LPS- 
stimulated RAW 264.7 cells, suggesting that there are additional signaling pathways 
activated by LPS stimulation in RAW 264.7 cells.
It has been known that LPS treatment activates NF-kB transcription factor that 
leads to the induction of many immediate early gene expressions (Baeuerle, 1991). It 
has been reported that a specific DNA sequence recognized by activated NF-kB, which 
is called the cw-acting NF-kB element, is present in the promoter region of COX-2 gene 
(Fletcher et al., 1992; Inoue et a l,  1995; Kosaka et al., 1994; Sirois et al., 1993; 
Yamamoto et al., 1995). Newton et al. (1997) demonstrated that in epithelial cells, 
which play a major role in inflammation, pro-inflammatory cytokines, such as 
interleukin (IL)-ip, rapidly induce NF-kB DNA binding and cause up-regulation of NF- 
kB-dependent genes, including COX-2 gene. These observations suggest that the 
activation of NF-kB may be an additional signaling event activated by LPS, which leads 
to COX-2 expression in RAW 264.7 cells.
In unstimulated or resting cells, NF-kB is sequestered in the cytoplasm through a 
physical association with an inhibitor protein, IkB-a. The treatment o f cells with 
extracellular stimuli, including LPS, IL-ip or TNF-a, results in the specific 
phosphorylation o f two serine residues on IkB-a protein followed by the ubiquitination
93
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(Roff et al., 1996) and then the degradation o f this inhibitor protein by some proteases 
(Thanos and Maniatis, 1995). The degradation of IkB-a protein releases free and active 
NF-kB, which then translocates from the cytoplasm to the nucleus and activates the 
transcription of specific target genes (DiDonato et al., 1995). Since the activation of 
NF-kB correlates with a rapid proteolytic degradation of IkB-a protein (Siebenlist et al., 
1994; DiDonato et al., 1995), our studies revealed that the degradation of IkB-a protein 
induced by LPS indicates the activation of NF-kB in RAW 264.7 cells. LPS treatment 
at 30 minutes results in almost complete degradation of IkB-a protein in RAW 264.7 
cells (Figure 7E, and 10A), indicating the release of active NF-kB. However, after 30 
minute LPS stimulation, the protein levels of IkB-a are fully recovered to its basal level 
before LPS treatment (Figure 10 A). Our results indicate that the degradation of IkB-a 
induced by LPS (or the activation of NF-kB induced by LPS) is a rapid and transient 
event.
Recently, DiDonato et al. (1995) applied Z-LLF-CHO, which is a multicatalytic 
protease complex (MPC) inhibitor, to demonstrate that the degradation of IkB-a is 
required for the activation of NF-kB. Using Z-LLF-CHO as the NF-kB inhibitor, we 
tested whether the inhibition of NF-kB activation might result in the inhibition of COX- 
2 expression in LPS-stimulated RAW 264.7 cells.
Z-LLF-CHO treatment that blocked LPS-induced degradation of IkB-a in a 
concentration-dependent manner (Figure 10B) also resulted in the suppression of COX- 
2 expression in LPS-stimulated RAW 264.7 cells (Figure 10C). These results indicate 
that the inhibition of NF-kB may be involved in the suppression o f COX-2 expression in 
LPS-stimulated RAW 264.7 cells. Our studies suggest that the activation o f NF-kB may
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be involved in the expression of COX-2 in LPS-stimulated RAW 264.7 cells. This view 
is also supported by the findings that activators of MAPKs, such as PMA, H2O2, 
sorbitol or a combination of these agents that failed to induce COX-2 mRNA expression 
(Figure 7C) and PGE2 production (Figure 7D) and also did not induce the degradation 
of IkB-a (the activation of NF-kB) (Figure 7E). Only LPS treatment resulted in the 
activation of NF-kB by the degradation of IkB-a in RAW 264.7 cells (Figure 7E, and 
10 A). Z-LLF-CHO treatment, however, does not affect phosphorylation of MAPKs in 
LPS-stimulated RAW 264.7 cells (Figure 10D), indicating that the regulatory 
mechanism of NF-kB is independent from that of MAPKs in RAW 264.7 cells.
Herbitnycin A is a  protein tyrosine kinase (PTK) inhibitor (Fukasawa et a l,
1991) and interferes with IL-la-induced NF-kB activation in T and B cells (Iwasaki et 
a l, 1992). Weinstein et a l  (1992) demonstrated that Herbimycin A treatment inhibits 
tyrosine phosphorylation of MAPKs and reduces the release of arachidonic acid 
metabolites, such as PGE2 . These observations imply that there may be a link between a 
protein phosphorylation of MAPKs and the production of arachidonic acid metabolites, 
which are major products by COX. Radicicol is an inhibitor of v-Srcp60 PTK (Kwon et 
a l, 1992). As noted previously, Radicicol and Herbimycin A inhibit the expression of 
COX-2 in LPS-stimulated rat alveolar macrophages (Chanmugam et al., 1995; Feng et 
a l,  1997) and RAW 264.7 cells (Gang, 1996). Previous results in this dissertation study 
have also suggested that the activation of MAPKs and NF-kB may be involved in the 
expression o f COX-2 in LPS-stimulated RAW 264.7 cells. Using Radicicol and 
Herbimycin A, we examined whether both inhibition of MAPKs and NF-kB might 
result in the inhibition o f COX-2 expression in  LPS-stimulated RAW 264.7 cells.
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Results by Gang (1996) demonstrated that Radicicol and Herbimycin A 
treatment resulted in the inhibition of LPS-induced tyrosine phosphorylation o f MAPKs 
(ERK-1, ERK-2, and P38 MAP kinase) in LPS-stimulated RAW 264.7 cells. Similarly, 
our results showed that the treatment of Radicicol and Herbimycin A resulting in 
inhibition of activation of LPS-induced tyrosine phosphorylation, activation of MAPKs 
(ERK-1, ERK-2, P38 MAP kinase, and JNK-1) and NF-kB also caused the inhibition of 
COX-2 expression in LPS-stimulated RAW 264.7 cells (Figure 11A to 1 IE). The 
current results demonstrate that both LPS-induced activation of MAPKs and NF-kB 
appears to be necessary for the expression o f COX-2 in LPS-stimulated RAW 264.7 
cells.
Several Src-family PTKs, in association with cell surface receptor proteins, 
participate in normal signaling pathways in hemopoietic cells, including monocytes and 
macrophages (Bolen et al., 1992). The major cell surface receptor for LPS on 
macrophages is CD14, a 55-kDa glycosyl-phosphatidylinositol (GPI)-anchored 
membrane protein (Han et al., 1993; Kielian et al., 1995). Three members o f Src-family 
PTKs, Lyn, Hck, and Fgr, are strong candidates for the primary signal transducers of 
LPS responses (Meng et al., 1997). All three of these kinases are rapidly activated 
following LPS treatment. It has been reported that a portion of intracellular Lynp53/56, 
which is one o f 9 Src-family PTKs, directly co-associates with CD 14 in human 
monocytes (Stefanova et al., 1993). These observations suggest that Src-family PTKs 
as upstream activators play critical roles in LPS-initiated or LPS/CD14-mediated signal 
transduction pathways in monocytes and macrophages. So far, the functional roles of
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Src-family PTKs on the expression of COX-2 in LPS-stimulated RAW 264.7 cells is not 
clearly understood.
It has been demonstrated that both tyrosine phosphorylation and expression level 
of Lynp53/56 was specifically inhibited by a PTK inhibitor Radicicol, which inhibits the 
expression of COX-2 in LPS-stimulated rat alveolar macrophages (Chanmugam et al., 
1995). This observation implicates Src-family PTKs as upstream activators in LPS 
signaling pathways, which leads to COX-2 expression in macrophages.
Xie et al. (1991) reported that many immediate early gene expressions, including 
COX genes, are induced in Rous sarcoma virus (RSV)-infected chicken embryo 
fibroblasts (CEF) in which v-Srcp60 was constitutively expressed. This observation 
suggests a critical role of the tyrosine residue at the C-terminal regulatory domain in 
regulating Src kinase activity and also implies the induction of many immediate early 
gene expressions by Src-family kinases by a single amino acid change. As noted 
previously, both tyrosine phosphorylation and expression level of Lyn kinase were 
specifically inhibited by Radicicol treatment, which causes the suppression of COX-2 
expression in LPS-stimulated rat alveolar macrophages (Chanmugam et al., 1995).
These observations implicated Lyn kinase in LPS signaling pathways leading to COX-2 
expression in macrophages. Based on these observations, we tested whether 
overexpression of mutant Lyn might result in the induction of COX-2 expression in 
mutant lyn DNA-transfected NIH/3T3 cells.
The two isoforms of Lynp53/56, which are derived from a single gene by 
alternative splicing o f the RNA transcripts, differ in the presence or absence of a 21- 
amino acid sequence (Stanley et al., 1991). Because o f the complete coding sequence,
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the 56 kDa isoform of Lyn (Lynp56) was chosen for this gene transfection study. Flag 
DNA sequence encoding 8 amino acids was placed at the C-terminus of the lyn DNA 
insert in the retroviral vector pBPSTR.1 to avoid the detection of any endogenous Lyn 
kinase not containing the Flag epitope. In addition to mutant lyn DNA encoding mutant 
Lyn, vector DNA alone and wild type lyn DNA encoding normal Lyn was included in 
transfection experiments.
The high expression of wild type and mutant Flag-tagged Lynp56 was detected 
by anti-Lyn and anti-Flag antibodies in wild type and mutant lyn DNA-transfected $>NX 
cells (Figure 12A, and 12B). Similarly, anti-Lyn or anti-Flag antibodies detected highly 
expressed wild type and mutant Flag-tagged Lynp56 in wild type and mutant lyn DNA- 
infected NIH/3T3 cells (Figure I2C to 12E). These results indicate that wild type and 
mutant lyn DNAs were appropriately transfected to <t>NX cells and they encoded a 56 
kDa molecular weight of Lyn in transfected and infected cells.
Since the exact downstream substrate of Lyn kinase has not yet been identified, 
an acid-denatured enolase was used as a general exogenous substrate in an 
immunecomplex kinase assay to measure Lyn kinase activity. The extent of 
incorporated y-P32 in enolase by wild type or mutant Lynp56 was assessed as an 
indication of Lyn kinase activity. Our studies revealed that the extent of 
autophosphorylation of wild type LynpS6 is much higher than that of mutant Lyn p56 
(Figure 12F). It is likely that wild type LynpS6 doubly autophosphorylated at both the 
397-tyrosine position in the protein kinase domain and the 508-tyrosine position in the 
C-terminal regulatory domain. In contrast, mutant Lynp56 became only 
monophosphorylated at the 397-tyrosine position in the protein kinase domain because
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of lack of the 508-tyrosine in the C-terminal regulatory domain, resulting in a lower 
phosphorylation level. Wild type Lynp56 phosphorylates enolase, whereas mutant Lyn 
p56 does not phosphorylate enolase (Figure 12F), suggesting that only wild type Lynp56 
had kinase activity. However, this may be the case only in an in vitro system because 
enolase is not the downstream substrate of Lyn in an in vivo system. Therefore, it 
should be noted that this might be different in vivo system.
Surprisingly, the recent results by Donella-Deana et al. (1998) indicated that the 
spontaneous autophosphorylation o f Lyn at both the protein kinase domain and the C- 
terminal regulatory domain causes different substrate specificity. According to these 
researchers, upon autophosphorylation, Lyn becomes doubly autophosphorylated 
molecules (at both tyrosine-397 and tyrosine-508) that possess an active catalytic 
domain by their increased affinity toward peptide substrates. Donella-Deana et al. 
(1998) also found that there is a novel conformation of Lyn that is catalytically active 
despite the presence of an intramolecular interaction between the phosphorylated 
tyrosine residue at the C-terminal regulatory domain and the SH2 domain, and this 
novel conformation appears to show a reduced oncogenic potential resulting from its 
defective recognition of a subset o f protein substrates whose targeting is mediated by 
the SH2 domain o f Lyn. It also has been explained that while double 
autophosphorylation of Lyn stimulates the kinase activity of Lyn toward peptide 
substrates, it actually prevents the phosphorylation o f protein substrates by Lyn, such as 
phospho-p50/HS 1 (hematopoietic-lineage cell specific protein) (Yamanashi et al., 1993) 
andp57/PDI (protein disulfide-isomerase) (Donella-Deana et al., 1996), whose 
multiphosphorylation requires the accessibility o f the SH2 domain (Brunati et al., 1995;
99
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Ruzzene et al., 1996; Donella-Deana et al., 1996). Based on these observations, it may 
be hypothesized that the autophosphorylation o f wild type Lynp56 occurred at both the 
397-tyrosine position in the protein kinase domain and the 508-tyrosine position in the 
C-terminal regulatory domain, and the double phosphorylated wild type Lyn p56 is likely 
to have a higher affinity toward enolase that may not have the SH2 domain, resulting in 
the increased phosphorylation of enolase. In contrast, mutant Lynp56 that is only 
monophosphorylated at the 397-tyrosine position in the protein kinase domain may have 
no affinity (or very low affinity) toward enolase because of the absence o f the SH2 
domain in enolase, or a high affinity toward protein substrates containing the SH2 
domain in infected NIH/3T3 cells.
Although the validity o f  this hypothesis will require further testing, the current 
transfection study found an interesting observation that overexpression o f mutant Lyn 
p56 induces high COX-2 expression and PGE2  production in NIH/3T3 cells (Figure 13 A 
and 13C). It has been known that some intracellular effectors that are physically 
associated with Lyn include phospholipase C-y2 (PLC-y2), phosphatidylinositol 3- 
kinase (PI 3-K), and GTPase-activating protein (GAP) (Pleiman et al., 1993). SH2 
interactions with tyrosine phosphoproteins are believed to play an important role in 
regulating signal transduction. Since PLC-y2, GAP, and PI 3-K are potentially tyrosine 
phosphorylated, their binding to Lynp56 may be mediated by the SH2 domain o f Lyn 
(Pleiman et al., 1993).
Further studies are needed to determine which intracellular effector molecules 
interact with mutant Lynp56 in infected NIH/3T3 cells by co-immunoprecipitation and 
whether they are either directly or indirectly involved in the expression of COX-2 in
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infected NIH/3T3 cells. Further studies are also required to confirm that the high 
induction of COX-2 expression from mutant lyn DNA-infected NIH/3T3 cells results 
from overexpression of mutant Lynp56 alone by the approach of co-transfection of a 
dominant-negative mutant Lyn DNA, which encodes a catalytically inactive Lyn kinase, 
into the NIH/3T3 cells.
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CHAPTER 5 
SUMMARY AND CONCLUSIONS
In this dissertation, the mechanism of COX-2 expression induced by LPS in 
RAW 264.7 cells was examined. The results can be summarized as follows. LPS- 
induced activation of MAPKs (ERK-1, ERK-2, P38 MAP kinase, and JNK-1) might be 
involved in the expression of COX-2 in LPS-stimulated RAW 264.7 cells. This was 
supported by the results that the partial inhibition of LPS-induced activation of MAPKs 
by inhibitors of MAPKs, such as PD98059 or SB203580, resulted in the partial 
suppression of COX-2 expression in LPS-stimulated RAW 264.7 cells. However, LPS- 
induced activation of MAPKs alone appeared to be insufficient to induce the expression 
of COX-2 in LPS-stimulated RAW 264.7 cells, suggesting that there are additional 
signaling pathways activated by LPS, which leads to the expression of COX-2. This 
was supported by the observations that activators of MAPKs, such as PMA, sorbitol, 
H2O2, or combinations of these agents failed to induce COX-2 expression in RAW
264.7 cells. NF-kB activation might be an additional signaling pathway activated by 
LPS, which leads to COX-2 expression in RAW 264.7 cells. This was supported by the 
results that acute LPS treatment caused the activation of MAPKs and also resulted in the 
maximal degradation of IkB-a protein, thereby releasing active NF-kB. Activators of 
MAPKs, such as PMA, sorbitol, H2O2, or combinations of these agents that activated 
MAPKs did not induce the degradation of IkB-a protein, indicating no activation of NF- 
kB. No induction of COX-2 expression by these agents in RAW 264.7 cells was 
correlated with no activation of NF-kB by these agents. LPS-induced activation o f NF- 
kB appeared to be involved in the expression of COX-2 in LPS-stimulated RAW 264.7
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cells. This was supported by the observations that the inhibition of LPS-induced 
activation of NF-kB by the inhibitor o f NF-kB, Z-LLF-CHO, resulted in the suppression 
of COX-2 expression in LPS-stimulated RAW 264.7 cells. Z-LLF-CHO treatment, 
however, did not affect LPS-induced tyrosine phosphorylation of MAPKs, indicating 
that LPS-induced activation of NF-kB signaling pathway was different from LPS- 
induced activation of MAPKs signaling pathway. Both LPS-induced activation of 
MAPKs and NF-kB were likely to be involved in the expression of COX-2 in LPS- 
stimulated RAW 264.7 cells. This was supported by the results that both inhibition of 
LPS-induced activation of MAPKs and NF-kB by Radicicol and Herbimycin A 
treatment caused the inhibition of COX-2 expression in LPS-stimulated RAW 264.7 
cells. Finally, overexpression of mutant Lynp56 induced high COX-2 expression and 
high production of PGE2  in mutant lyn DNA-transfected NIH/3T3 cells.
The current study concludes that LPS-induced COX-2 expression is likely to be 
mediated via rapid LPS-induced activation of MAPKs and NF-kB in LPS-stimulated 
RAW 264.7 cells. Transfection data also demonstrate an interesting observation that 
overexpression of mutant Lynp56 leads to induce high COX-2 expression and high 
production o f PGE2 in mutant lyn DNA-transfected NIH/3T3 cells.
Future research will have to confirm the expression of COX-2 induced by 
overexpression of mutant Lynp56 in NIH/3T3 cells by co-transfection of a dominant- 
negative mutant Lynp56. Future studies also will have to include the finding of 
intermediate signaling molecules between mutant Lyn and COX-2 expression using the 
NIH/3T3 cells. Further studies also will have to find whether overexpression of mutant 
Lyn kinase also induces COX-2 expression in macrophages or macrophage-like cell
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lines. Future studies also will have to determine the role o f each subfamily of MAPKs 
and NF-kB on the expression of COX-2 and PGE2  production by transfection of each 
DNA into RAW 264.7 cells. Any future studies also will have to find the functional 
role o f Lyn on the activation of MAPKs and/or NF-kB in LPS signaling pathways. The 
current study and further research may provide an insight to understand the LPS 
signaling pathways leading to COX-2 expression and PGE2 production, which are 
responsible for inflammation.
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APPENDIX
LIST OF ABBREVIATIONS
AA Arachidonic acid
API Activator protein 1
AP-1 A synonym of API
AP2 Activator protein 2
ATF2 Activating transcription factor 2.
ATP Adenosine triphosphate
BMM Bone marrow-derived macrophage
BSA Bovine serum albumin
cAMP Cyclic AMP
cDNA Complementary DNA
CEFs Chicken embryo fibroblasts
COX-1 Cyclooxygenase-1.
COX-2 Cyclooxygenase-2.
CPLA2 Cytosolic phospholipase A2
CRE Cyclic AMP response element
cRNA Complementary RNA
CSAIDs Cytokine-suppressive anti-inflammatory drugs
Csk C-terminal Src kinase
dATP Deoxyadenosine triphosphate
DMEM Dulbecco’s modified Eagle’s medium
DNA Deoxyribonucleic acid
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DTT Dithiothreitol
ECL Enhanced chemiluminescence
EDTA Ethylenediaminetetraacetic acid
EGF Epithermal growth factor
EPA Eicosapentaenoic acid
ERKs Extracellular signal-regulated kinases
ERK-1 Extracellular signal-regulated kinase-1
ERK-2 Extracellular signal-regulated kinase-2
ERK-3 Extracellular signal-regulated kinase-3
ERK-4 Extracellular signal-regulated kinase-4
ERK-5 Extracellular signal-regulated kinase-5
FBS Fetal bovine serum
GAP GTPase-activating protein
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
Glu Glutamate
Gly Glycine
GPI Glycosylphosphatidylinositol
GSH Glutathione
GST Glutathione S-transferase
GST-ATF2 Glutathione S-transferase-activating transcription factor 2
Hck Hematopoietic cell kinase
HEPES jV-2-hydroxyethylpiperazine-Ar’-2ethanesulphonic acid
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HIV Human immunodeficiency virus
HPETEs Hydroperoxy-5,8,12, 14-eicosatetraenoic acids
HS1 Hematopoietic-lineage cell specific protein
Ig Immunoglobulin
IgG Immunoglobulin G
IkB Inhibitory kappa B
IkB-a Inhibitory kappa B-a
IL Interleukin
EL-1 Interleukin-1
IMP Immunoprecipitattion
IPTG Isopropyl-p-thio-galactopyranoside
JNKs c-Jun N-terminal kinases
JNK-1 c-Jun N-terminal kinase-1
JNKK c-Jun N-terminal kinase kinase
LB media Luria Bertani media
LBP LPS-binding protein
LPS Lipopolysaccharide.
LTs Leukotriens
Lyn Lck/yes-related novel tyrosine kinase
MAPKs Mitogen-activated protein kinases.
MAPKK-1 Mitogen-activated protein kinase kinase-1
MAPKK-2 Mitogen-activated protein kinase kinase-2
MBP Myelin basic protein
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MEK-1 A synonym of MAPKK-1
MEK-2 A synonym of MAPKK-2
MEK-6 A synonym of MKK-6
MKK-1 A synonym of MAPKK-1
MKK-2 A synonym of MAPKK-2
MKK-3 Mitogen-activated protein kinase kinase-3
MKK-4 Mitogen-activated protein kinase kinase-4
MKK-6 Mitogen-activated protein kinase kinase-6
MPC Multicatalytic protease complex
NF-kB Nuclear factor-kappa B
NSAIDs Nonsteroidal anti-inflammatory drugs
OD Optical density
PBS Phosphate-buffered saline
PBST Phosphate-buffered saline-Tween 20
PDGF Platelet-derived growth factor
PDI Protein disulfide-isomerase
PDTC Pyrolidinedithiocarbamate
PGs Prostaglandins
PGE, Prostaglandin Ei
p g e 2 Prostaglandin E2
p g e 2 Prostaglandin E2
p g g 2 Prostaglandin G2
p g h 2 Prostaglandin H2
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PGH Prostaglandin H synthase
PGIs Prostacyclins
PGS-2 Prostaglandin synthase-2
PI3-K Phosphatidylinositol 3-kinase
PKC Protein kinase C
PMSF Phenylmethylsulfonicfluoride
PK.s Protein kinases
PLC-y2 Phospholipase C-y2
PMA Phorbol 12-myristate 13-acetate
PPs Protein phosphatases
Pro Proline
PTKs Protein tyrosine kinases
PUFAs Polyunsaturated fatty acids
PVDF Polyvinylidene difluoride
RHD Rel homology domain
RIA Radioimmunoassay
RIPA Radioimmunoassay precipitation buffer
RK Reactivating kinase
RNA Ribonucleic acid
ROIs Reactive oxygen intermediates
RPA Ribonuclease protection assay
RSK Ribosomal S6 protein kinase
RSV Rous sarcoma virus
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SAPKs' Stress-activated protein kinases
SDS Sodium dodecyl sulfate
SEK-1 Stress-activated kinase-1
Ser Serine
SH-2 Src homology-2
SH-3 Src homology-3
SMC Smooth muscle cell
SRE Serum response element
TBS Tris-buffered saline
TBST Tris-buffered saiine-Tween 20
TCA Trichloroacetic acid
TE (pH 8.0) 10 mM Tris-Cl, pH 8.0/lmM EDTA, pH 8.0
Thr Threonine
TNF Tumor necrosis factor
TNF-a Tumor necrosis factor-a
TPA 12- Otetradecanoylphorbol-13-acetate
Tris Tris(hydroxymethyl)aminomethane
TXs Thromboxanes
Tyr Tyrosine
UV Ultraviolet
Z-LLF-CHO Benzyloxy-carbonyl-Leu-Leu-phenylalaninal
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